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Abbreviations  
CDH1 E-cadherin 
CMS consensus molecular subtype 
COAD colon adenocarcinoma 
CRC colorectal cancer 
CRIS colorectal cancer intrinsic subtypes 
EMT epithelial-mesenchymal transition 
MET mesenchymal-epithelial transition 
EMT-TF EMT-inducing transcription factor 
GSEA gene set enrichment analyses 
MSP methylation-specific PCR 
STAT3 signal transducers and activators of transcription 3 
FCS fetal calf serum 
DMSO dimethyl-sulfoxide 
APS ammonium peroxodisulfate 
TEMED tetramethylethylendiamin,1,2-bis (dimethylamino) –ethan 
SDS sodium dodecyl sulfate 
WB Western blot analysis 
IHC immunohistochemical analysis 
cDNA complementary DNA 
E.coli Escherichia coli 
DNA deoxyribonucleic acid 
DOX doxycycline 
HBSS Hank’s balanced salt solution 
PCR polymerase chain reaction 
siRNA small interfering rna 
PDX patient-derived xenografts 
PTP- ζ protein-tyrosine phosphatase ζ 
qChIP quantitative chromatin immunoprecipitation 
READ rectal adenocarcinoma 
TCGA the cancer genome atlas 
TSA trichostatin A 
TSS transcriptional start site  
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VIM vimentin 
3′-UTR three primed untranslated region 
5-aza 5-aza-2'deoxycytidine 
5-FU 5-fluoro-uracil 
ZEB zinc finger E-box-binding homeobox protein 
miRNAs micro RNAs 
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1. Introduction 
1.1 Colorectal Cancer: 
Colorectal cancer (CRC) is the third most common cancer but second in terms of 
mortality globally (Dekker, Tanis, Vleugels, Kasi, & Wallace, 2019) (Figure 1.1). 
Despite the big efforts in prevention, diagnosis, and treatment in the past decades, 
more than 1.81 million new CRC patients were diagnosed and 881,000 deaths are 
estimated to occur in 2018 (Bray et al., 2018).  
      
Figure 1.1: The distribution of the new diagnosed cases and death in 2018. 
(Figure taken from Freddie Bray, et al. CA: A Cancer Journal for Clinicians, 2018 (Bray 
et al., 2018)) 
 
Although genetic inheritance is an important risk factor for CRC, the majority of 
CRC cases occurred in people without a family history of CRC or inherited gene 
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mutation that could increase the risk of CRC, suggesting the acquired somatic genetic 
and epigenetic alterations largely contributed to the CRC risk (Smith et al., 2018). The 
CRC incidence rates between countries show a great variation and are correlated with 
the human development index (HDI) that used to reflect the county’s economic 
development (Khazaei et al., 2016) (Figure 1.2). Accordingly, developed countries 
have higher CRC incidence rates than undeveloped countries, which is probably due 
to the sedentary lifestyle, westernized dietary and increasing obesity, since all of them 
are major risk factors for CRC. Moreover, age-standardized incidence rates also vary, 
highlighting that CRC is a consequence of combined risk factors, including genetics 
and lifestyle. Of note, the rising incidence of CRC at younger ages is an emerging trend.  
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Figure 1.2 
A, The ranking of cancer mortality of countries. 
B, Global Maps Present  the 4-Tier Human Development Index. 
Figures taken from (Bray et al., 2018) 
 
CRC carcinogenesis is considered to represent a stepwise process and each 
step is associated with distinct molecular changes. In the past, Fearon and Vogelstein 
described a model in which the accumulation of sequential alterations of several tumor-
suppressive and tumor-driven genes results in the “adenoma to carcinoma cascade” 
(Fearon & Vogelstein, 1990) (Figure 1.3). In this cascade, the inactivation of APC 
initiates the transformation from mucosa to adenoma, followed by the alteration of 
KRAS and p53, which further drives the aggressiveness of subclones. This model was 
well-accepted as it was the foundation on which the strategy of CRC prevention is 
based. However, some of the CRC lack alterations of APC and KRAS showing that 
CRC is a heterogeneous disorder and indicating that the linear theory is not applicable 
to all the cases of CRC (Jass, 2007).               
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Figure 1.3: Genetic changes associated with the “adenoma to carcinoma cascade”. 
Figure taken from https://basicmedicalkey.com/colorectal-cancer-2/ 
 
1.2 Molecular Subtypes of CRC  
CRC is a heterogeneous disease and composed of biologically and clinically diverse 
subtypes. An appropriate subtype classification that correlates molecular changes in 
tumors with clinical relevance can better describe the tumor behavior and may improve 
prognosis and treatment strategies.  
 
1.2.1 Consensus Molecular Subtypes (CMS) 
With the increasing molecular and genomic study of CRC, a number of genes 
expression-based CRC classification systems were proposed which grouped 
colorectal cancer into subgroups with distinct molecular and clinical features (Jass, 
2007). Among those classifications, the consensus molecular subtypes (CMS) 
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classification is one of the most robust colorectal cancer classifications and widely 
accepted. It grouped CRCs into 4 subtypes (CMS1-CMS4) with distinguishing features: 
CMS1, hyper-mutated, microsatellite unstable, strong immune activation; CMS2, 
epithelial, chromosomally unstable, marked WNT and  MYC signaling activation; 
CMS3, epithelial, evident metabolic dysregulation; and CMS4, prominent transforming 
growth factor β activation, stromal invasion, and angiogenesis (Guinney et al., 2015). 
The CMS classification has prognostic value independent of the cancer stage. For 
example, patients with CMS4 subtype have poor survival, even when treated with 
standard adjuvant chemotherapies (Sveen et al., 2018). In addition, it also shows the 
advantage of predicting the response to treatments. Okita et al. studied the association 
between CMS subtypes and treatment outcomes, showing that this classification could 
be a predictive factor for the efficacy of chemotherapy against CRC (Okita et al., 2018). 
 
1.2.2 CRC Intrinsic Subtypes (CRIS) 
The CMS classification was created by using 18 datasets and collectively more than 
4000 CRC samples (Guinney et al., 2015). However, the tumor samples might be 
contaminated by infiltrated stromal cells. Thus the molecular features in each CMS 
subtype represent a mixture of those from tumor cells and stromal cells (Isella et al., 
2015). For example, a large portion of the genes involved in the CMS4 signature may 
be derived from tumor stroma. Such stromal cells may, for instance, be tumor-
associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs), which are 
strong indicators of tumor aggressiveness, but do not represent tumor cell inherent 
functions (Calon et al., 2015; Isella et al., 2015). To solve this problem, patient-derived 
xenografts (PDX) have been used to generate mRNA expression signatures by 
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microarray analyses. By the use of human-specific probe sets the contribution of 
(murine) stromal mRNAs to whole tumor mRNA expression patterns was selectively 
eliminated (Isella et al., 2017). Thereby, five different colorectal cancer intrinsic 
subtypes (CRIS-A to CRIS-E) were defined. Among those five CRIS subtypes, CRIS-
B shows the poorest prognosis and is enriched with signatures associated with EMT. 
Apart from classifying PDX-derived tumors, this classification system was used to re-
classify previously established publicly available CRC patient cohorts into CRIS 
subtypes, such as the TCGA-COAD cohort (Isella et al., 2017) 
 
1.3 CRC Metastasis and EMT 
1.3.1 CRC Metastasis 
Metastasis, which is defined as the spread of tumor cells from the original tumor site 
to a secondary site within the patients, is the main cause of cancer-related death in the 
vast majority of cancer types, including CRC (Boire, Brastianos, Garzia, & Valiente, 
2020; Favoriti et al., 2016). The most common site of metastasis for CRC is the liver 
(Dekker et al., 2019). In addition, metastatic tumors were also found in the lungs, brain, 
bones, or spinal cord. While surgery still remains the most effective and mainstay 
treatment option for CRC, most CRC patients with distant metastasis are not suitable 
for conventional therapy, leading to poor 5-year survival of <10% (Brenner, Kloor, & 
Pox, 2014; Manfredi et al., 2006). In most of CRC patients, metastasis occurred before 
the surgical resection or was found at the time of surgery, resulting in a high risk of 
recurrence. However, the mechanism underlying metastasis has not been fully 
discovered, which limits the strategy of prevention, early diagnosis, therapeutic 
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treatment, and prognosis. Therefore, a better understanding of the molecular 
mechanism is urgently needed.  
 
1.3.2 Epithelial-mesenchymal transition (EMT) 
Epithelial-mesenchymal transition (EMT) of primary tumor cells is one of the first steps 
of the metastatic cascade in epithelium-derived carcinomas (Nieto, Huang, Jackson, & 
Thiery, 2016). EMT is accompanied by the downregulation of epithelial gene 
expression and the upregulation of mesenchymal gene expression. The key events in 
EMT are the dissolution of the epithelial cell-cell junctions to detach from the primary 
tumor and get into the surrounding tissues.  Tumor cells that underwent an EMT 
acquire an increased capability of motility and invasion by expressing matrix 
metalloproteinase that can degrade extracellular matrix proteins (De Craene & Berx, 
2013; Thiery, Acloque, Huang, & Nieto, 2009). Therefore, tumor cells are able to invade 
into the bloodstream or lymphatic system, and subsequently establish metastasis.    
 
1.3.3 EMT regulation in CRC 
Several transcription factors that repress the epithelial phenotype and induce the 
mesenchymal phenotype are critical for EMT, such as SNAIL, TWIST and zinc-finger 
E-box-binding (ZEB) transcription factors (Hahn & Hermeking, 2014; Hahn, Jackstadt, 
Siemens, Hunten, & Hermeking, 2013). One of the hallmarks of EMT is the down-
regulation of E-cadherin. SNAIL represses E-cadherin and other epithelial genes by 
binding to their promoter, thereby decreasing cell-cell adhesion (Peinado, Ballestar, 
Esteller, & Cano, 2004). In addition, SNAIL also down-regulates mesenchymal-to-
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epithelial transition (MET)-inducing genes, such as miR-200c and miR-34a/b/c, by 
directly binding to the promoter (Gill et al., 2011; Hahn et al., 2013; Siemens et al., 
2011). As a member of the SNAIL family, SLUG is also responsible for EMT and tumor 
metastasis via repression of E-Cadherin (Bolos et al., 2003). The expression of ZEB1 
and ZEB2 often follows the activation of SNAIL expression. ZEB1 and ZEB2 act as 
both transcriptional repressors and activators, thereby repress some epithelial junction 
and polarity genes and activate mesenchymal genes that define the EMT phenotype 
(Krebs et al., 2017). Besides, TWIST also plays an essential role in EMT and cancer 
metastasis (Kang & Massague, 2004). TWIST directly induces SLUG by binding its 
promoter. Additionally, TWIST represses E-cadherin independently SNAIL. Moreover, 
TWIST cooperates with SNAIL in the induction of ZEB1 expression.  
 
1.4 p53/miR-34a 
1.4.1 The tumor suppressor p53 
p53 is one of the most important suppressors of tumor formation and is also the 
most frequently mutated gene in human cancer. For instance, up to 50%-70% of 
colorectal tumors harbor p53 mutations (Chung, 2000). In unstressed cells, the p53 
protein is degraded through the ubiquitin-proteasome pathway and is thereby 
maintained at a low level. A number of intracellular and extracellular stresses, such as 
DNA damage, induce the activation of p53. Upon the stimulation, the half-life of p53 
protein is increased, leading to an accumulation of p53 protein in cells. The activated 
p53 binds to specific DNA sequences in the promoter of target genes, thereby 
regulating cancer cell metabolism, invasion, metastasis, apoptosis, cell cycle arrest 
and DNA repair (Rokavec, Li, Jiang, & Hermeking, 2014a) (Figure 1.4).  Thereby, p53 
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eliminates damaged or mutant cells that could potentially become cancer cells. On the 
contrary, defective p53 allows abnormal cells to proliferate. Besides protein-encoding 
genes, microRNA can also be targeted directly by p53. 
  
1.4.2 miRNAs and miR-34a family 
microRNAs (miRNAs) are a class of short, endogenous RNAs of 19-25 nucleotides in 
size (Hermeking, 2012). So far, hundreds of miRNAs have been found and identified 
in animals, plants, and viruses. miRNAs are critical for a variety of biological processes 
by targeting mRNAs for degradation or translation repression. In general, the host 
genes of miRNA are transcribed to a primary miRNA (pri-miRNA), which is further 
processed to a precursor miRNA (pre-miRNA) by a class 2 RNase enzyme Drosha in 
nuclear (Rokavec et al., 2014a; Rokavec, Li, Jiang, & Hermeking, 2014b). Next, the 
pre-miRNAs are transported to the cytoplasm by exportin-5. In the cytoplasm, the pre-
miRNAs are cleaved by another RNase III nuclease Dicer, resulting in a 22 bp double-
stranded RNA (miRNA: miRNA* duplex). Mostly one strand is loaded into the RNA-
induced silencing complex (RISC) in which the miRNA interacts with its target mRNA, 
whereas the other strand is degraded. After loading, the miRNA guides the RISC to its 
target mRNA to repress translation or induce mRNA degradation.   
Certain miRNAs are induced by p53 and displayed a tumor-suppressive function 
(Hermeking, 2012). Among these p53-induced miRNAs, miRNAs of the miR-34 family 
often show the most pronounced induction by p53 (Rokavec, Li, Jiang, & Hermeking, 
2014). The miR-34 family consists of miR-34a, miR-34b, and miR-34c. Of the 3 
members of the miR-34 family, the expression of miR-34a was found in most of the 
human tissue, while the miR-34b/c were mainly expressed in specific organs, such as 
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lungs and brain. In humans, the host gene of miR-34a is located on chromosome 1, 
whereas the host gene of miR-34b and miR-34c is located on chromosome 11. 
Chromatin immunoprecipitation and luciferase reporter assays showed that both host 
genes of the miR-34 family contain p53-responsive elements where p53 binds directly 
to activate the transcription (Hermeking, 2007; Tarasov et al., 2007). Upon p53 
induction, the elevated expression of miR-34a/b/c inhibits the progression of cancer by 
down-regulation of multiple proteins, such as SNAIL, ZNF281, IL6R, INH3 and PAI-1, 
suggesting miR-34 family represent important mediators of tumor suppressor p53 
(Hahn et al., 2013; Li, Rokavec, Jiang, Horst, & Hermeking, 2017; Oner et al., 2018; 
Rokavec, Oner, et al., 2014; Siemens et al., 2011) (Figure 1.4). Besides p53-induced 
expression of miR-34 family, the level of miR-34a/b/c can be regulated by other factors, 
such as FoxO3a, ELK1, STAT3 and HIF1alpha (Christoffersen et al., 2010; Li, Rokavec, 
et al., 2017; Natarajan et al., 2017; Rokavec, Oner, et al., 2014).   
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Figure 1.4  
The role of p53/miRNA axis in (A) p53 autoregulation, (B) cancer cell metabolism, (C) 
invasion, and metastasis, as a result of the regulation of EMT/MET (D) cancer-
associated inflammatory signaling. Figure taken from (Rokavec, Li, et al., 2014) 
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1.4.3 miR-34 in CRC 
The potential tumor-suppressive effect of the miR-34 family attracted researchers to 
investigate their role in cancer.  The members of the miR-34 family exhibit tumor 
suppressor effects, by inhibiting the process that promotes tumor development, such 
as EMT, cell cycle, and stemness, and promoting processes that inhibit tumor growth, 
such as apoptosis and senescence. These processes are regulated via the repression 
of miR-34target mRNA.   
In CRC, it has been shown miR-34 inhibits cell migration, invasion and metastasis 
by downregulation of IL6R, ZNF281, c-Kit and Pai-1. In a model of Apcmin/+ mice with 
deletions of the miR-34a and/or miR-34b/c genes, the tumor burden was increased 
while the life-span survival was decreased (Jiang & Hermeking, 2017). In another 
AOM/DSS treated mice model for the study of colon carcinogenesis, loss of miR-34a 
facilitated tumor invasion, accompanied by characteristics of EMT and enhanced IL-
6R/STAT3 signaling. These findings demonstrated the tumor-suppressive function of 
miR-34 in CRC. Moreover, miR-34a directly suppresses the EMT transcriptional factor 
SNAIL, therefore inhibiting EMT. Interestingly, miR-34a is also repressed by SNAIL, 
thus the balance between miR-34a and SNAIL determines, at least in part, the 
epithelial or mesenchymal state of tumor cells. 
Notably, the expression of the miR-34 family is frequently inactivated in a number 
of tumor types. In CRC, the expression of miR-34a and miR-34b/c is downregulated in 
tumors when compared with adjacent non-tumor tissues. Besides the mutation of p53, 
the CpG methylation in the promoter of miR-34a/b/c genes significantly contributes to 
the lower expression of miR-34 in CRCs and has been associated with distant 
metastasis (Lodygin et al., 2008; Oner et al., 2018; Siemens, Neumann, et al., 2013; 
Vogt et al., 2011). The methylation of miR-34a and miR-34b/c was frequently found in 
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CRC samples, with a rate of 74% and 99% of samples respectively. Compared with 
miR-34b/c, the level of miR-34a is higher in CRC. Therefore, many studied in CRC 
focused on the regulation and function of miR-34a. 
 
1.5 CSF1R signaling pathway  
Together with the PDGFR and c-kit receptors, the colony-stimulation factor 1 receptor 
(CSF1R), which is encoded by the c-fms proto-oncogene, belongs to the group of type 
III RTKs (Heisterkamp N Fau - Groffen, Groffen J Fau - Stephenson, & Stephenson, 
1983; Roussel, Sherr, Barker, & Ruddle, 1983; Yarden & Ullrich, 1988). Transforming 
potential has been assigned to the viral homolog (v-fms) and c-fms (Coussens et al., 
1986; Roussel et al., 1987). Binding of its ligand CSF1 or the more recently identified 
ligand, IL-34, induces homodimerization and activation of CSF1R (Ullrich & 
Schlessinger, 1990; Y. Wang et al., 2012). Subsequently, the Ras/Raf/MAPK, 
PI3K/AKT, and JAK/STAT pathways are activated (Lemmon & Schlessinger, 2010; 
Novak et al., 1995; Ullrich & Schlessinger, 1990) (Figure 1.5). CSF1R was initially 
identified and shown to be mainly expressed in macrophages and their progenitors 
(Byrne, Guilbert, & Stanley, 1981; Guilbert & Stanley, 1980), where the CSF1R-
mediated signaling is crucial for the survival and differentiation. Tumor-associated 
macrophages (TAM), which are recruited to tumors through the secretion of various 
chemotactic molecules, such as CSF1, have been associated with poor survival in 
various tumor types (Cannarile et al., 2017; Chockalingam & Ghosh, 2014). In early 
stage as well as metastatic cancer, the dominant TAM phenotype was reported to be 
tumor-promoting M2 macrophages as opposed to tumor suppressive M1 macrophages. 
CSF1/CSF1R signaling is critical for the polarization and maintenance of M2 
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macrophages, that promote tumor growth, angiogenesis, invasion, and metastasis as 
well as resistance to therapy (Zhao et al., 2015). In addition, paracrine interactions 
between tumor cells and TAMs facilitate the spread of a tumor by promoting migration, 
invasion, and metastasis (Wyckoff et al.). Accordingly, the intra-tumoral presence of 
TAM is associated with poor survival. Thus, targeting the CSF1/CSF1R axis in tumor-
promoting TAM has been represented as a potential and attractive strategy to eliminate 
or repolarize these cells. For example, CSF1R inhibition reduced the M2 macrophage 
polarization and blocked tumor progression in glioma (Pyonteck et al., 2013). Moreover, 
various approaches targeting CSF1R signaling are currently in clinical development 
(Cannarile et al., 2017).  
 
Figure 1.5 Signaling pathways regulated by CSF1R in myeloid cells (Figure taken from 
(Pixley & Stanley, 2004).) 
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In addition to macrophages, the expression of CSF1R and its ligands can be 
detected in several types of tumors, including CRC (Cioce et al., 2014; Julia Menke et 
al., 2012; Patsialou et al.). As a receptor tyrosine kinase, the biological activity of 
CSF1R is largely based upon ligand stimulation. It has been shown that not only 
CSF1R but also CSF1 and IL34, are overexpressed in CRC (Franze et al., 2018b; H. 
Wang et al., 2016). In the human colon expression of CSF1 is significantly higher than 
that of IL34, suggesting CSF1 is the main ligand for activation of CSF1R in CRC 
(Zwicker et al., 2015). However, the significance of CSF1R-expressing tumor cells of 
epithelial origin is less well characterized. Interestingly, elevated expression of CSF1 
and CSF1R in breast cancer has been associated with metastases and progression 
(Richardsen, Uglehus, Johnsen, & Busund, 2015). Notably, colorectal cancer patients 
with a more advanced tumor stage display elevated serum levels of CSF1, implying 
that CSF1R signaling may be involved in CRC progression (Mroczko, Szmitkowski, & 
Okulczyk, 2003). 
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2. Aims of the study 
The present study had the following aims: 
• Analysis of the putative associations and prognostic value of CSF1R, CSF1 and 
IL34 expression in CRC patient cohorts 
• Characterization of the putative regulation of CSF1R by miR-34a in colorectal 
cancer cells. 
• Determination of the relevance of CSF1R regulation by miR-34a for EMT, 
migration, invasion, metastasis, and chemo-resistance in CRC 
• Analysis of the potential association of miR-34a silencing with CSF1R up-
regulation in CRC cells and patient samples  
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3. Materials  
3.1 Chemicals and Reagents 
Chemical compound Supplier 
FCS Life Technologies  
Penicillin-Streptomycin (10,000 U/mL) Life Technologies 
DMEM medium Life Technologies  
Mc Coy’s medium Life Technologies 
HBSS, no calcium, no magnesium, no phenol red Life Technologies 
etoposide Sigma-Aldrich 
5-FU Sigma-Aldrich 
DMSO Carl Roth 
Boric acid Sigma-Aldrich 
Fast SYBR® Green Master Mix Applied Biosystems 
Fast SYBR Green Master Mix Universal RT Exiqon A/S 
Protein A-Sepharose® from Staphylococcus aureus Sigma-Aldrich 
Rotiphorese gel 30 (37,5:1) Carl Roth 
APS Carl Roth 
TEMED Carl Roth 
Nonidet®P40 substitute Sigma-Aldrich 
sodium deoxycholate  Carl Roth 
SDS Carl Roth 
β-mercaptoethanol Sigma-Aldrich 
glycerol Carl Roth 
Tris base Sigma-Aldrich 
bromophenol blue Carl Roth 
complete mini protease inhibitor cocktail Roche 
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Chemical compound Supplier 
PhosSTOP Phosphatase Inhibitor Cocktail  Roche 
Bradford reagent Bio-Rad 
PageRuler™ Prestained Protein Ladder Fermentas 
Immobilon-P PVDF,0.45μm Membrane Merck Millipore 
skim milk powder Sigma-Aldrich 
Methanol Carl Roth 
ECL/HRP substrate Merck Millipore 
DAPI  Carl Roth 
EDTA Sigma-Aldrich 
BD Matrigel™ Basement Membrane Matrix BD Bioscience 
Triton X 100 Carl Roth 
Protein G Sepharose®, Fast Flow Sigma-Aldrich 
BSA fatty acid free Sigma-Aldrich 
Salmon Sperm DNA Promega 
37% formaldehyde Merck Millipore 
ampicillin Sigma-Aldrich 
water (molecular biological grade) Life Technologies  
LB-Agar (Lennox) Carl Roth 
LB-Medium (Luria/Miller) Carl Roth 
Hi-Di™ Formamide Applied Biosystems 
sea plaque® agarose Lonza 
O’Gene Ruler 1kb DNA ladder Fermentas 
ethidium bromide Carl Roth 
HiPerFect Transfection Reagent Qiagen 
Opti-MEM® Reduced Serum Medium Life Technologies 
ampicillin Sigma-Aldrich 
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Chemical compound Supplier 
water (molecular biological grade) Life Technologies 
LB-Agar (Lennox) Carl Roth 
LB-Medium (Luria/Miller) Carl Roth 
Hi-Di™ Formamide Applied Biosystems 
sea plaque® agarose Lonza 
O’Gene Ruler 1kb DNA ladder Fermentas 
ethidium bromide Carl Roth 
Lipofectamine® 2000 Transfection Reagent Invitrogen 
Chloroquine Sigma-Aldrich 
Opti-MEM® Reduced Serum Medium Life Technologies 
puromycin dihydrochloride Sigma-Aldrich 
Doxycycline  Sigma-Aldrich 
Crystal violet Carl Roth 
Acetic acid Carl Roth 
Methanol Carl Roth 
Mitomycin C  Sigma-Aldrich 
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3.2 Cell Lines 
 
 
3.3 Buffers and Solutions 
3.3.1 Buffers for Western Blot: 
Laemmli buffer (2x):  
125 mM TrisHCl (pH 6.8)  
4% SDS 
20% glycerol 
0.05% bromophenol blue (in H2O) 
10% β-mercaptoethanol (added right before use) 
RIPA buffer:  
1% NP40 
Cell lines Medium 
DLD-1  
McCoy’s 5A medium with 10% FBS and 1% Pen/strep 
 
HT29 
HCT15 
RKO TP53-/- 
RKO TP53+/+ 
SW480 DMEM medium with 10% FBS and 1% Pen/strep 
SW620 
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0.5% sodium deoxycholate;  
0.1% SDS 
250 mM NaCl 
50 mM TrisHCl (pH 8.0)  
Tris-glycine-SDS running buffer (10x):  
720 g Glycin 
150 g Tris base 
50 g SDS 
pH 8.3-8.7 
add ddH2O up to 5 l 
Towbin buffer:  
200 mM glycine 
20% methanol 
25 mM Tris base (pH 8.6) 
TBST (10x):  
500 ml 1M Tris (pH 8.0) 
438.3 g NaCl 
50 ml Tween20 
add ddH2O up to 5 l 
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3.3.2 Buffers for MTT: 
SDS-0.01M HCl: 
10g SDS  
0.1ml HCl (10M) 
add ddH2O up to 100 ml 
 
3.3.3 Buffer for PCR: 
‘Vogelstein‘ PCR buffer (10x):  
166 mM NH4SO4 
670 mM Tris (pH 8.8) 
67 mM MgCl2 
100 mM β-mercaptoethanol  
3.3.4 Cell Culture Medium: 
90% Mc Coy’s 5A medium or DMEM medium 
10% FBS 
100 U/ml penicillin 
100 µg/ml streptomycin 
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3.3.5 Cell Freezing Medium: 
40% Mc Coy’s 5A medium or DMEM medium 
50% FBS 
10% DMSO 
3.3.6 Buffers for Methylation-specific PCR 
TBE buffer (10X, 1L): 
54 g of Tris base (CAS# 77-86-1) 
27.5 g of boric acid (CAS# 10043-35-3，H3BO3) 
20 ml of 0.5 M EDTA (CAS# 60-00-4) (pH 8.0) 
Adjust pH to 8.3 by HCl. 
 
3.4 Kits 
Kit Supplier 
High Pure RNA Isolation Kit Roche 
BCA Protein Assay Kit  Thermo Fisher Scientific 
QIAamp DNA Micro Kit QIAGEN 
High Pure RNA Isolation Kit Roche 
Verso cDNA Kit Thermo Fisher Scientific 
QIAquick Gel Extraction Kit QIAGEN 
QIAquick PCR Purification Kit QIAGEN 
Pure Yield™ Plasmid Midiprep System Promega 
QIAprep Spin Miniprep Kit QIAGEN 
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Kit Supplier 
BigDye® Terminator v3.1 Cycle Sequencing Kit  Life Technologies 
DyeEx® 2.0 Spin Kit QIAGEN 
EZ DNA Methylation Kits Zymo Research 
QuikChange  II XL Site-Directed Mutagenesis Kit Agilent Technologies 
DNeasy Blood & Tissue Kit  Qiagen 
Dual-Luciferase® Reporter Assay System Promega 
 
 
3.5 Enzymes 
Enzyme Use Supplier 
Trypsin-EDTA  cell culture Invitrogen 
DNase I  qPCR Sigma-Aldrich 
restriction endonucleases  vectors generation New England Biolabs 
Platinum® Taq DNA polymerase  vectors generation Invitrogen 
Pfu polymerase  vectors generation Thermo Fisher Scientific 
T4 DNA ligase  vectors generation Thermo Fisher Scientific 
 
3.6 Oligonucleotides 
3.6.1 Oligonucleotides used for qPCR  
Gene Sequence (5’-3’) 
β-actin_For TGACATTAAGGAGAAGCTGTGCTAC 
β-actin_Rev GAGTTGAAGGTAGTTTCGTGGATG 
CSF1R_For CCTCGCTTCCAAGAATTGCA 
CSF1R_Rev CCCAATCTTGGCCACATGA 
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Gene Sequence (5’-3’) 
CSF1_For GCAAGAACTGCAACAACAGC 
CSF1_Rev ATCAGGCTTGGTCACCACAT 
pri-miR-34a_For CGTCACCTCTTAGGCTTGGA  
pri-miR-34a_Rev CATTGGTGTCGTTGTGCT 
CDH1_For  CCCGGGACAACGTTTATTAC  
CDH1_Rev GCTGGCTCAAGTCAAAGTCC 
VIM_For TACAGGAAGCTGCTGGAAGG  
VIM_Rev ACCAGAGGGAGTGAATCCAG 
SNAIL_For GCACATCCGAAGCCACAC  
SNAIL_Rev GGAGAAGGTCCGAGCACAC 
ZEB1_For TCAAAAGGAAGTCAATGGACAA  
ZEB1_Rev GTGCAGGAGGGACCTCTTTA 
 
 
3.6.2 Oligonucleotides used for MSP and BSP 
 Sequence (5’-3’) 
MSP_M_For GGTTTTGGGTAGGCGCGTTTC 
MSP_M_Rev TCCTCATCCCCTTCACCGCCG 
MSP_U_For (Inosine)(Inosine)GGTTTTGGGTAGGTGTGTTTT 
MSP_U_Rev AATCCTCATCCCCTTCACCACCA 
BSP_For TAGAGATAATAGGTTTTGATTCGGGATAGA 
BSP_Rev CAAAACTCCCACAAAATCTCCAAATACCCCC 
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3.6.3 Oligonucleotides used for qChIP 
Gene Sequence (5’-3’) 
CSF1R_For ACAACTTTCCCACCAGTCCT 
CSF1R_Rev GGGGTGAGTAGTTTGGTGGG 
MiR-200c_For CAGGAGGACACACCTGTGC 
MiR-200c_Rev TCCCCTGGTGGCCTTTAC 
AchR_For CCTTCATTGGGATCACCACG 
AchR_Rev AGGAGATGAGTACCAGCAGGTTG 
 
 
3.6.4 Oligonucleotides used for cloning and mutagenesis of the CSF1R 3’-UTR 
gene  Sequence (5’-3’) 
Human CSF1R 3’UTR_For CGGAATTCGGAGTTGACGACAGGGAG
 Human CSF1R 3’UTR_Rev CGCTGCAGATGTGGACAGAGACATCC
 
Human CSF1R 3’UTR mutant_For CCTGAGCATGGGCCATCAGTCGGAGT
 
Human CSF1R 3’UTR mutant_Rev CCCCCAGCCCCTGACTCCGACTGATG
 
Human CSF1R (L301S) _For GAGAGTGCCTACTCGAACTTGAGCTCT   
Human CSF1R (L301S) _Rev AGAGCTCAAGTTCGAGTAGGCACTCTC 
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3.6.5 Oligonucleotides (pre-miR-34a, antagomir miR-34a) 
 
 
3.7 Antibodies 
3.7.1 Primary Antibodies 
epitope  catalog no. company use dilution source 
α-tubulin # T-9026 Sigma-Aldrich WB 1:1000 mouse 
β-actin # A2066 Sigma-Aldrich WB 1:1000 rabbit 
p53 # sc-126 Santa Cruz WB 1:1000 mouse 
E-cadherin  # 334000 Invitrogen WB 1:1000 mouse 
CSF1R # HPA012323  Sigma-Aldrich WB 1:1000 rabbit 
Vimentin # 2707-1 Epitomics WB 1:1000 rabbit 
SNAIL  # 3879S Cell Signaling WB 1:500 rabbit 
ZEB1 # sc-25388 Santa Cruz WB 1:1000 rabbit 
STAT3pS727 # 9134 Cell Signaling WB 1:1000 rabbit 
STAT3 # sc-482 Santa Cruz WB 1:1000 rabbit 
VSV # V4888 Sigma-Aldrich WB; ChiP 1:1000 rabbit 
CSF1R # sc-692 Santa Cruz WB 1:500 rabbit 
 
product  Sequence (5’-3’) Company  
pre-miR-34a  GGCCAGCUGUGAGUGUUUCUUU
GGCAGUGUCUUAGCUGGUUGUU
GUGAGCAAUAGUAAGGAAGCAA
UCAGCAAGUAUACUGCCCUAGA
AGUGCUGCACGUUGUGGGGCCC 
Thermo Fisher Scientific 
antagomir  
miR-34a 
UUGCCAGGCAGUGUAGUUAGCU
GAUUGACGAGGCAACAGUCACU
AACAACACGGCCAGGUGA 
Thermo Fisher Scientific 
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3.7.2 Secondary Antibodies 
name ordering no. company use dilution source 
anti-mouse HRP # W4021  Promega WB 1:10.000 goat 
anti-rabbit HRP # A0545  Sigma WB 1:10.000 goat 
 
 
3.8 Vectors 
Name Insert Reference 
pRTR -- (Jackstadt et al., 2013) 
pRTR-p53-VSV  human p53  (Hunten et al., 2015) 
pRTR-miR-34a human miR-34a (Kaller et al., 2011) 
pRTR-SNAIL human SNAIL (Siemens et al., 2011) 
pRTR-SLUG human SLUG (Rokavec, Kaller, Horst, & 
  pRTR-CSF1R human CSF1R  
pRTR-CSF1R (L301S) human CSF1R (L301S)  
pGL3-control-MCS -- (Welch, Chen, & Stallings, 
 
pGL3-CSF1R wt human CSF1R 3’UTR  
pGL3-CSF1R mut human CSF1R 3’UTR  
pRL Renilla (Pillai et al., 2005) 
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3.9 siRNAs  
siRNA Supplier 
negative control #4611, Ambion 
siRNA STAT3 #6880, Ambion 
siRNA CSF1R SMART pool, Dharmacon 
 
 
3.10 Softwares  
Application Software Supplier 
Data analysis SPSS Statistics 23.0 IBM 
Data analysis and 
figure generation 
Graphpad Prism8.0 Graph Pad Software 
Inc. 
Figure composition Adobe Illustrator Adobe 
WB Varioskan Flash Spectral Scanning 
Multimode Reader 
Thermo Scientific 
Image Studio™ Lite LI-COR Biosciences 
qPCR NanoDrop 1000 Spectrophotometer Thermo Scientific 
Sequencing analysis DNASTAR Lasergene Software DNASTAR 
BioEdit BioEdit 
qPCR LightCycler 480  Roche 
Wound healing assay Axiovision Zeiss 
Morphology  Axiovision Zeiss 
IHC Axiovision Zeiss 
Luciferase reporter 
assays 
SIMPLICITY software package DLR 
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Application Software Supplier 
Modified Boyden-
chamber 
Axiovision Zeiss 
Xenograft IVIS Illumina System Caliper Life 
Sciences 
Ectopic expression BD Accuri™ C6 Cytometer BD Biosciences 
 
 
3.11 Laboratory equipment  
Device Supplier 
Cell culture flasks, Multiwall plates 
and Conical Tubes 
Corning Incorporated, USA 
Neubauer counting chamber Carl Roth 
Axiovert 25 Inverted Microscope Carl Zeiss Meditec AG, 
Germany 
AxioPlan 2 Microscope System Carl Zeiss Meditec AG, 
Germany 
Microcentrifuge Thermo Fisher Scientific 
Inc.,USA 
Mastercycler™ pro PCR System Eppendorf GmbH, Germany 
NanoDrop® ND-1000 
Spectrophotometer 
Thermo Fisher Scientific 
Inc.,USA 
Boyden chamber transwell membranes Corning 
Culture-Insert 2 Well ibidi 
Waterbath WNB 45 Memmert GmbH + Co. 
KG,Germany 
ABI 3130 genetic analyzer capillary sequencer Applied Biosystems 
biophotometer plus eppendorf 
BD AccuriTM C6 Flow Cytometer Instrument BD Accuri 
Forma scientific CO2 water jacketed incubator Thermo Fisher Scientific 
EPS 600 power supply Pharmacia Biotech 
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Device Supplier 
Orion II luminometer Berthold Technologies 
IVIS Illumina System Caliper Life Sciences 
Mini-PROTEAN®-electrophoresis system Bio-Rad 
PerfectBlue™ SEDEC ‘Semi-Dry’ blotting system Peqlab Biotechnologie 
HTU SONI130 G. Heinemann Ultraschall- und 
Labortechnik 
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4. Methods  
4.1 Cell culture and treatments 
The CRC cell lines HCT-15, RKO, HT29, and DLD-1 were maintained in McCoy’s 5A 
Medium (Invitrogen) containing 10% fetal bovine serum (FBS, Invitrogen), SW480 and 
SW620 cell lines were maintained in Dulbecco`s Modified Eagles Medium (DMEM, 
Invitrogen) containing 10% FBS. p53-/- and p53+/+ RKO cell lines were kindly provided 
by Bert Vogelstein (Johns Hopkins University, Baltimore). All cells were cultivated in 
the presence of 100 units/ml penicillin and 0.1 mg/ml streptomycin at 20% O2, 5% CO2 
and 37°C. Doxycycline (Dox) (Sigma-Aldrich) was dissolved in water (100 μg/ml stock 
solution) and always used at a final concentration of 100 ng/ml. Recombinant Human 
CSF1 (BioLegend) was dissolved in water and used at a final concentration of 50 ng/ml 
with daily refreshment. pre-miRNAs mimics (PM11030, Ambion), miRNA antagomirs, 
and respective negative controls (Ambion-Applied Biosystems) were transfected using 
HiPerfect (Qiagen). siRNAs (Ambion silencer siRNA: negative control [ID#4611], 
siRNA STAT3 [ID#6880], and Dharmacon: siRNA CSF1R [SMART pool]) were 
transfected at a final concentration of 20 nM using Lipofectamine 2000 (Invitrogen). 
 
4.2 Modified Boyden-chamber assay 
Migration and invasion analyses were performed as described previously (Rokavec, 
Oner, et al., 2014). In brief, cells were serum-starved for 24 hours. For the migration 
assay, 5x104 cells were seeded in the upper chamber (8.0 µm pore size membrane; 
Corning) in a serum-free medium. For invasion assays, chamber membranes were first 
coated with Matrigel (BD Bioscience) at a dilution of 3.3 ng/ml in medium without serum. 
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Then 5x105 cells were seeded on the Matrigel in the upper chamber in serum-free 
medium. As chemo-attractant, 10% FCS was placed in the lower chamber. After cells 
were cultured for 36 hours, non-motile cells at the top of the filter were removed and 
the cells in the bottom chamber were fixed with methanol, stained with crystal violet. 
Relative invasion/migration was normalized to the corresponding control. 
 
4.3 Western blot analysis  
SDS-PAGE and Western blot analyses were performed as described previously (Li, 
Rokavec, et al., 2017). Cells were lysed in RIPA lysis buffer (50 mM Tris/HCl, pH 8.0, 
250 mM NaCl, 1% NP40, 0.5% (w/v) sodium deoxycholate, 0.1% sodium dodecyl 
sulfate, complete mini protease inhibitors (Roche) and PhosSTOP Phosphatase 
Inhibitor Cocktail Tablets (Roche)). Lysates were sonicated and centrifuged at 
16.060 g for 20 min at 4°C. 30-80 μg protein were separated on 7.5%, 10% or 12% 
SDS-acrylamide gels. Gel electrophoresis and transfer to Immobilon PVDF 
membranes (Millipore) were carried out using standard protocols (Bio-Rad 
laboratories). Primary antibodies were used in combination with HRP-coupled 
secondary antibodies. ECL (Millipore) signals were recorded with a 440CF imaging 
system (Kodak). Antibodies used here are listed in chapter 3.7. 
 
4.4 Chromatin immunoprecipitation (ChIP) 
DLD1/pRTR-SNAIL-VSV cells were cultured as described above. Before cross-linking, 
cells were treated with Dox [100 ng/ml] for 24 hours to induce ectopic expression of 
VSV-tagged proteins. Cross-linking was conducted with formaldehyde (Merck) at 1% 
                                                                                                                          Methods 
 
36 
 
final concentration and terminated after 5 minutes by addition of glycine at a final 
concentration of 0.125 M. Cells were harvested in SDS buffer (50 mM Tris pH 8.1, 0.5% 
SDS, 100 mM NaCl, 5 mM EDTA), pelleted and resuspended in IP buffer (2 parts of 
SDS buffer and 1 part Triton dilution buffer (100 mM Tris-HCl pH 8.6, 100 mM NaCl, 5 
mM EDTA, pH 8.0, 0.2%  NaN3, 5.0% Triton X-100)). Chromatin was sheered by 
sonication (HTU SONI 130, G. Heinemann) to generate DNA fragments with an 
average size of 500 bp. Preclearing and incubation with polyclonal VSV antibody 
(V4888, Sigma) for 16 hours was performed as previously described (Hahn et al., 2013; 
Menssen et al., 2007). Washing and reversal of cross-linking was performed as 
described (Amati, Frank, Donjerkovic, & Taubert, 2001). Immunoprecipitated DNA was 
analyzed by qRT-PCR and the enrichment was expressed as a percentage of the input 
for each condition. The sequences of oligonucleotides used as qChIP primers are listed 
in chapter 3.6.3. 
 
4.5 Generation of cell pools stably expressing conditional alleles 
Stably transfected cells were generated by transfection of the episomal expression 
vector pRTR using Fugene6 (Roche) and selected with incrementally increasing 
concentrations of Puromycin (0.5-6.0 µg/ml) for 10 days (Siemens et al., 2011).  The 
frequency of GFP-positive cells was determined 48 hours after the addition of Dox at 
a final concentration of 100 ng/ml by flow cytometry.  
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4.6 Dual 3’-UTR luciferase reporter assays 
The full-length 3’-UTRs of the human CSF1R mRNA were PCR-amplified from cDNA 
of human diploid fibroblasts. The PCR product was cloned into the shuttle vector 
pGEM-T-Easy (Promega), and then transferred into the pGL3-control-MCS vector 
(Welch et al., 2007) and verified by sequencing. For mutagenesis of the miR-34a seed-
matching sequences, the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene) 
was used according to the manufacturer’s instructions and verified by sequencing. 
H1299 cells were seeded in 12-well plate at 3×104 cells/well for 24 hours and 
transfected for 72 hours with 100 ng of the indicated firefly luciferase reporter plasmid, 
20 ng of Renilla reporter plasmid as a normalization control and 25 nM of miR-34a pre-
miRNA oligonucleotide (Ambion, PM11030), or a negative control oligonucleotide 
(Ambion, neg. control #1) with HiPerFect Transfection Reagent (Qiagen) for 48 hours. 
The analysis was performed with the Dual-Luciferase Reporter assay (Promega) 
according to the manufacturer’s instructions. Fluorescence intensities were measured 
with an Orion II luminometer (Berthold) in 96-well format and analyzed with the 
SIMPLICITY software package (DLR). The sequences of oligonucleotides used for 
cloning and mutagenesis of human 3‘-UTR are listed in chapter 3.6.4. 
 
4.7 Bioinformatic analysis of online databases  
The Cancer Genome Atlas (TCGA) gene expression data and follow-up information of 
colon adenocarcinomas (COAD) were downloaded from the NCI's Genomic Data 
Commons (GDC) (https://gdc.cancer.gov/) (Network, 2012). Normalized RSEM counts 
were used to determine the expression of relevant mRNAs. Pearson for analysis of 
expression correlation was performed with the Prism5 program (Graph Pad Software 
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Inc.). Association of patient samples with the different CMS categories was obtained 
from the Cancer Subtyping Consortium (CRCSC) at www.synapse.org. The CMS 
subtypes were described in (Guinney et al., 2015). CMS-specific signature gene sets 
were obtained from (Sveen et al., 2018). PDX RNA expression data of human CRC 
specimens (GSE76402), the classification of CRC intrinsic subtypes (CRIS) and the 
respective signature genes for each CRIS subtype were obtained from (Isella et al., 
2017). Single-cell RNA expression data of normal colonic and CRC cells (GSE81861) 
were obtained from (Li, Courtois, et al., 2017) and analysed with the RCA R package 
as described. Expression and clinical data of GSE37892, GSE39582, and GSE14333 
datasets were downloaded from NCBI GEO (www.ncbi.nlm.nih.gov/geo). Gene Set 
Enrichment Analysis (GSEA) was performed on pre-ranked gene lists based on 
expression correlation coefficients (Pearson) with CSF1R using the GSEA software 
obtained from http://software.broadinstitute.org/gsea/index.jsp (Subramanian et al., 
2005). Hallmark gene sets were obtained from the Molecular Signatures Database 
(MSigDB) (Liberzon et al., 2015). Heatmaps were generated with GENE-E (Broad 
Institute). 
 
4.8 Clinical samples and immunohistochemistry 
CSF1R expression was evaluated using formalin-fixed, paraffin-embedded (FFPE) 
colon cancer samples of 90 patients who underwent surgical tumor resection at the 
Ludwig-Maximilians University Munich. Tissue microarrays (TMAs) were generated 
with 6 representative 1 mm cores of each case, for which the methylation status of 
miR-34a had been determined previously (Siemens, Neumann, et al., 2013). The TMA 
sections were deparaffinized and stained with the human CSF1R antibody (ab183316, 
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Abcam) on a Benchmark XT Autostainer with UltraView Universal DAB and alkaline 
phosphatase detection kits (Ventana Medical Systems). The stainings were evaluated 
according to the score shown in Figure 5.40A. 
 
4.9 Colony formation assay 
For low-density, colony formation assays, 500 cells were seeded into a 6-well plate 
and cultivated for 24 hours in the presence or absence of Dox or CSF1 for 24 hours, 
and subsequently treated with or without 5-FU for 72 hours. Cells were washed once 
with HBSS, a new medium was added and cells were allowed to recover for two days 
before fixation and crystal violet staining. 
 
4.10 Wound healing assay 
Mitomycin C [10 ng/ml] was added two hours before generating a scratch using a 
Culture-Insert (IBIDI, 80241). Cells were allowed to close the wound for the indicated 
periods and images were captured on an Axiovert Observer Z.1 microscope connected 
to an AxioCam MRm camera using the Axiovision software (Zeiss) at the respective 
time-points. 
 
4.11 Detection of apoptosis 
Apoptosis rates were determined by flow cytometry after staining with Annexin V-FITC 
(apoptotic cell marker) and PI (necrotic cell marker) according to the Annexin V-
FITC/PI staining kit (BD Pharmingen, 556570). In brief, treated and control cells were 
                                                                                                                          Methods 
 
40 
 
harvested by the addition of trypsin (without EDTA) and washed twice with HBSS. Then 
cells were resuspended in 1 x binding-buffer (0.01 M HEPES/NaOH (pH 7.4), 0.14 M 
NaCl, 2.5 mM CaCl2 ) at a concentration of 1 x 106 cells/ml. 100 μl of the solution (1 x 
105 cells) was incubated with 5 μl of FITC Annexin V and 5 μl propidium iodide. Cells 
were gently agitated and incubated for 15 minutes at room temperature in the dark. 
Then 400 μl of the 1x binding-buffer was added to each tube and the samples were 
analyzed within 1 hour by flow cytometry (CFlow6, Accuri). 
 
4.12 MTT assay 
Cell viability was measured with a modified MTT assay (Septisetyani, Ningrum, 
Romadhani, Wisnuwardhani, & Santoso, 2014). In brief, CRC cells were seeded in 96-
well plates and treated with different doses of 5-FU for 48 hours, MTT was added at a 
concentration of 0.5 µg/µL four hours before addition of formazan solvents (10% SDS 
in 0.01 M HCL). Following overnight incubation in the dark, plates were agitated and 
the absorbance was measured at 570 nm.  
 
4.13 Establishment of a 5-FU-resistant cell pool 
5-FU-resistant cell pools were established by exposure to stepwise increasing 
concentrations of 5-FU. Initially, DLD1 and HT29 cells were cultured in medium 
containing 0.1 μmol/l 5-FU. The drug concentration was then increased in steps of 
1.25x increases from 0.1 μmol/l up to 30 μmol/l. Cells were cultured for at least one 
week at each step, with medium exchange every three days. The 5-FU-resistant cell 
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pool was designated DLD1_5FU and HT29_5FU, respectively. The tolerance towards 
5-FU was determined with an MTT assay.  
 
4.14 RNA isolation and qPCR analysis 
Total RNA was isolated with the High Pure RNA Isolation Kit (Roche) or RNAeasy Kit 
(Qiagen) according to the manufacturer´s protocol. cDNA was generated from 1 μg of 
total RNA per sample using the Verso cDNA synthesis kit (Thermo scientific). 
Quantitative real-time PCR (qPCR) was performed with the Fast SYBR Green Master 
Mix (Applied Biosystems) by using the LightCycler 480 (Roche). Expression was 
normalized using the detection of GAPDH or β-actin using the ΔΔCt method (Livak & 
Schmittgen, 2001). Results are represented as fold induction of the treated/transfected 
condition compared with the control condition. Experiments were performed in 
triplicates. The sequences of oligonucleotides used as qPCR primers are listed in 
chapter 3.6.1. 
 
4.15 Methylation-specific PCR 
Genomic DNA was isolated from cell lines using the DNeasy Blood & Tissue Kits 
(Qiagen). 400 ng of gDNA was treated with bisulfite using the EZ DNA methylation kit 
(Zymo Research, D5001 & D5002). The modified DNA was eluted with a final volume 
of 10 μl elution buffer. 3 μl were amplified by PCR. The MSP primers used for detection 
of CpG-methylation of the miR-34a promoter are depicted in chapter 3.6.2 and were 
previously established (Lodygin et al., 2008). The PCR protocol entailed 5 min at 95°C; 
two cycles of 95°C for 20 seconds, 68°C for 30 seconds, and 72°C for 30 seconds, 
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followed by two cycles with 66°C annealing temperature, then 34 cycles with 65°C 
annealing temperature, and a final elongation step at 72°C for 10 minutes. For the 
methylated allele a 122-bp fragment and for the unmethylated allele a 126-bp fragment 
were obtained. The PCR products were separated by electrophoresis on 8% 
polyacrylamide gels and then visualized by ethidium bromide staining.  
 
4.16 Bisulfite sequencing 
5 µl of bisulfite-treated genomic DNA was used as a template to amplify fragments of 
a 776 bp region upstream of the miR-34a promoter encompassing the transcription 
start site and p53 binding site with a high CpG content (Lodygin et al., 2008; Vogt et 
al., 2011). The bisulfite sequencing PCR (BSP) primers used here are depicted in 
Table 2, with PCR settings of 95°C for 5 minutes, followed by 38 cycles of 95°C for 20 
seconds, 65°C for 30 seconds, and 72°C for 60 seconds, with a final elongation step 
at 72°C for 10 minutes. Amplification products were purified using a QIAquick Gel 
Extraction Kit, and then subcloned into the shuttle vector pGEM-T-Easy (Promega). 
For each cell line at least 9 individual clones were sequenced on both strands using 
SP6 and T7 sequencing primers. The sequencing reactions were analysed on a 
capillary sequencer (ABI 3130, Applied Biosystems). Clones with a cytosine 
conversion rate of < 90% were excluded. Methylation data from bisulfite sequencing 
were trimmed, aligned and displayed as lollipop graphs using QUMA.  
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4.17 Metastasis formation in NOD/SCID mice 
Immune-compromised NOD/SCID mice were obtained from Jackson Laboratories. 
DLD-1 cells stably expressing Luc2 were produced as described previously (Shi et al., 
2014). DLD1-Luc/pRTR-CSF1R were generated by stable transfection of pRTR 
plasmids and maintained in medium with puromycin. 1 x 106 cells were resuspended 
in 0.2 ml HBSS and injected into the lateral tail vein of a 6- to 8-week-old age-matched 
male NOD/SCID mouse using a 25-gauge needle. For monitoring of the injected cells, 
anesthetized mice were injected i.p. with D-luciferin (150 mg/kg) and imaged with the 
IVIS Illumina System (Caliper Life Sciences) 10 minutes after injection. The acquisition 
time was set to 2 min and imaging was performed once a week. After 8 weeks, mice 
were sacrificed and the whole lungs were resected and subjected to H&E staining. All 
studies involving mice were performed with approval by the local Animal 
Experimentation Committee (Regierung of Oberbayern). All experiments were 
conducted following relevant guidelines and regulations. 
 
4.18 Statistics 
Calculations of significant differences between two groups of samples were analyzed 
by a Student’s t-test (unpaired, two tailed). For the comparison of multiple groups, a 
one-way analysis of variance followed by a Tukey multiple comparisons post-hoc test 
was performed. Log-rank test was used for the statistical analysis of the Kaplan-Meier 
curves. Cox proportional hazards models were applied for multiple regression analyses 
of survival data. The Association of CSF1R expression with clinical parameters was 
analyzed using chi-square tests. For mRNA expression correlation analyses, Pearson
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´s correlation was applied. P-values ≤ 0.05 were considered as significant. Asterisks 
generally indicate: *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. Statistics 
were calculated with Prism5 (Graph Pad Software Inc.) and SPSS (IBM). 
 
4.19 Study approval 
All experimentations involving mice were approved by the Government of Upper 
Bavaria, Germany (AZ-ROB-55.2-2532.Vet_02-18-57). Since the human tumor 
biopsies analyzed in Figure 5.40 and Figure 5.41 underwent dual anonymization a 
specific approval was not requested by the ethics committee of the Medical Faculty, 
Ludwig-Maximilians-University Munich. 
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5. Results 
5.1 Association of CSF1R, CSF1 and IL34 expression with clinical parameters 
in CRCs 
In order to determine the potential clinical relevance of CSF1R and its ligands in CRC, 
we analyzed their expression in 440 primary colorectal cancer (CRC) samples 
represented within the Cancer Genome Atlas (TCGA) database (Cancer Genome 
Atlas, 2012). Thereby, we found that increased expression of CSF1R, as well as 
CSF1 and IL-34 mRNAs, in primary CRCs was significantly associated with 
decreased survival of patients (Figure 5.1).  
 
 
Figure 5.1  
Kaplan-Meier analyses of survival with data from the TCGA database using log-rank 
tests. Below the graphs the numbers of patients with high or low expression of the 
indicated mRNA at the respective time point is provided. COAD: colorectal adenomas. 
mOS: median overall survival. HR: hazard ratio, CI: confidence interval. 
 
In another cohort of 566 CRC patient samples (Marisa et al., 2013), elevated 
CSF1R and CSF1, but not IL34, mRNA expression was associated with poor overall 
survival (Figure 5.2 A). Moreover, elevated CSF1R, CSF1, and IL-34 mRNA 
expression was also associated with decreased relapse-free survival in an 
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independent cohort comprising 130 patients (Laibe et al., 2012) (Figure 5.2 B). 
Therefore, we could confirm the findings obtained within the TCGA-COAD cohort in 
two independent CRC cohorts.  
 
 
Figure 5.2  
A, B, Kaplan-Meier analyses of survival with data from the (A) GSE39582 and the (B) 
GSE37892 cohorts using log-rank tests. Below the graphs the numbers of patients with 
high or low expression of the indicated mRNA at the respective time point is provided. 
COAD: colorectal adenomas. mOS: median overall survival. HR: hazard ratio, CI: 
confidence interval. 
 
The consensus molecular subtypes (CMS) classification is one of the most 
robust classification system for CRCs and is based on comprehensive gene 
expression profiles (Guinney et al., 2015). CRCs belonging to the consensus 
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molecular subtype 4 (CMS4), which displays a mesenchymal signature and the worst 
prognosis among the 4 different CMSs (Guinney et al., 2015), showed the highest 
expression of CSF1R, CSF1, and IL-34 (Figure 5.3 A). Next, we stratified CMS4 tumors 
into two subgroups with either elevated or low expression of CSF1R, CSF1 and IL-34 
mRNAs (Figure 5.3 B): Patients with CMS4 CRCs that displayed either high CSF1R, 
CSF1 or IL34 expression had a significantly shorter overall survival than patients with 
CRCs classified as CMS1-3 or CMS4 with low CSF1R or CSF1 or IL34 expression.  
 
 
Figure 5.3  
A, CSF1R, CSF1 and IL34 mRNA expression in CRCs belonging to the indicated 
consensus molecular subtypes (CMS). RSEM: RNA-Seq by Expectation Maximization. 
B, Kaplan-Meier analysis of overall survival of patients with primary CRCs classified 
as CMS1-3 or CMS4 with either high CSF1R/CSF1/IL34 or low CSF1R/CSF1/IL34 
expression levels. P1: CMShigh vs CMSlow; P2: CMShigh vs CMS1-3; P3: CMSlow vs 
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CMS1-3. The number of patients in each group was listed below the graph. mOS: 
median overall survival.  
(*) P < 0.05, (**) P < 0.01, (***) P < 0.001 and (****) P < 0.0001. 
Furthermore, also in the two other cohorts, expression levels of CSF1R and 
CSF1 were elevated in CMS4 tumors (Figure 5.4 A and B). 
 
 
Figure 5.4  
A, B, CSF1R, CSF1 and IL34 mRNA expression in CRC patient samples from the 
GSE37892 (A) and GSE39582 (B) datasets classified according to the indicated 
consensus molecular subtypes (CMS). (*) P < 0.05, (**) P < 0.01, (***) P < 0.001 and 
(****) P < 0.0001. 
 
 
However, mRNAs displaying elevated expression in CMS4 type tumors may 
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CRCs (Calon et al., 2015; Isella et al., 2017; Isella et al., 2015). To overcome this 
caveat, patient-derived xenografts (PDX) have been used to generate mRNA 
expression signatures by microarray analyses, where the contribution of (murine) 
stromal mRNAs to whole tumor mRNA expression patterns was selectively eliminated 
by the use of human-specific probe sets (Isella et al., 2017). Thereby, five different 
colorectal cancer intrinsic subtypes (CRIS) were defined. Apart from classifying PDX-
derived tumors, these were used to re-classify previously established publicly available 
CRC patient cohorts into CRIS subtypes, such as the TCGA-COAD cohort (Isella et 
al., 2017). Notably, CSF1R mRNA expression within the TCGA-COAD cohort was 
elevated in the CRIS-B subtype (Figure 5.5 A), which is characterized by TGF-β 
pathway activity, epithelial-mesenchymal transition and poor prognosis (Isella et al., 
2017). Moreover, expression of the CSF1 ligand, but not of IL34, was elevated in the 
CRIS-B subtype of tumors within the TCGA-COAD cohort. We validated these findings 
in the additional cohort comprising 566 cases. Again, expression of both CSF1R and 
its ligand CSF1, but not IL34, was elevated in CRIS-B tumors (Figure 5.5 B).  
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Figure 5.5 
A, B, The indicated mRNA expression in CRC patient samples from the TCGA-COAD 
(A) and GSE39582 (B) cohorts classified according to the indicated CRC intrinsic 
subtypes (CRIS). 
(*) P < 0.05, (**) P < 0.01, (***) P < 0.001 and (****) P < 0.0001. 
 
To further validate our findings, we also analyzed CSF1R expression in CRIS 
subtypes of PDX samples. CSF1R expression was elevated in the CRIS-B subtype 
when compared to the other subtypes, albeit without statistical significance in case of 
the CRIS-A and CRIS-D subtypes (Figure 5.6 A). Gene Set Enrichment Analyses 
(GSEA) showed a strong positive correlation of CSF1R mRNA expression with CRIS-
B and CMS4 gene signatures, whereas either negative or non-significant correlations 
of CSF1R mRNA with signatures from all other CRIS or CMS subclasses in PDX 
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samples were observed (Figure 5.6 B and C), indicating that tumor intrinsic CSF1R 
expression is associated with a mesenchymal tumor phenotype. In addition, elevated 
CSF1R expression was associated with CRIS-B/CMS4 associated signatures, such as 
EMT and IL6/JAK/STAT3 signalling. Moreover, mRNA expression data from whole 
tumors showed strong positive correlations of CSF1R with both CRIS-A and -B and 
CMS1 and -4, as well as EMT and IL6/JAK/STAT3 signalling associated signatures in 
the majority of analyzed patient cohorts.  
 
Figure 5.6 
A, The indicated mRNA expression in CRC patient samples from the PDX cohorts 
classified according to the indicated CRC intrinsic subtypes (CRIS). 
B, GSEA results for CSF1R expression from PDX, TCGA, and indicated GEO data 
sets. Genes were preranked by expression correlation coefficient (Pearson r) with 
CSF1R for each data set. 
C, CSF1 and IL34 mRNA expression in CRC patient samples from the GSE76402 
cohort classified according to the indicated CRC intrinsic subtypes (CRIS). 
C: Figures and analysis were made by Dr. Markus Kaller.  
(*) P < 0.05, (**) P < 0.01, (***) P < 0.001 and (****) P < 0.0001. 
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Furthermore, analysis of published single cell RNA sequencing results (Li, 
Courtois, et al., 2017) obtained from primary colorectal tumors and matched normal 
mucosa revealed that CSF1R is specifically expressed in colonic epithelial and tumor 
cells with stem/TA-like features (Figure 5.7 A and B).  
 
 
Figure 5.7 
A, CSF1R mRNA expression derived from single-cell sequencing data of normal 
colonic (n=160) and CRC tissue (n=271) (GSE81861).  
B, PCA plot based on the reference component analysis (RCA) scRNA–seq clustering 
algorithm showing the clustering of different cell types in tumor epithelial cells and cells 
from normal mucosa. CSF1R-expressing cells are highlighted as indicated. 
A, B: Figures and analysis were made by Dr. Markus Kaller.  
(*) P < 0.05, (**) P < 0.01, (***) P < 0.001 and (****) P < 0.0001. 
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Next we also evaluated association of CSF1R expression with other 
clinical/pathological variables in both the TCGA-COAD and the GSE39582 cohort in 
order to exclude potentially confounding factors that might affect patient survival. 
CSF1R expression did not display a significant association with age, gender and tumor 
stage (UICC). However, elevated CSF1R expression in CRCs was associated with 
mismatch-repair-deficient/MSI (microsatellite-instability), as well as with the CMS4 or 
CRIS-B molecular subtypes of CRCs (Table 1). A Cox multiple regression analysis 
demonstrated prognostic power of high CSF1R expression independent from age, 
gender, MSI status and tumor stage (Table 2). The GSE37892 cohort was not included 
here, since the necessary data was incomplete. 
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Table 1.  
Clinical data and CSF1R mRNA expression in colon cancer cases from two 
independent patient cohorts 
 TCGA-COAD GSE39582 
Characteristics Total CSF1R P Total CSF1R P 
    Low High     Low High   
All patients 440 (100.0) 335 (76.1) 105 (23.9)  566 (100.0) 532 (76.1) 34 (23.9)  
Age (years)           
     < median 206 (46.9) 164 (79.6) 42   (20.4) 0.109 283 (51.2) 272 (96.1) 11 (3.9) 0.033 
     ≥ median 234 (53.1) 171 (73.1) 63   (26.9)  282 (48.8) 259 (91.8) 23 (8.2)  
Gender           
     Male 235 (53.4) 182 (77.4) 53   (22.6) 0.490 310 (54.8) 290 (93.5) 20 (6.5) 0.624 
     Female 205 (46.6) 153 (74.6) 52   (25.4)  256 (45.2) 242 (94.5) 14 (5.5)  
UICC stage           
      I 73   (17.0) 58   (79.5) 15   (20.5) 0.378 33   (5.9) 33   (100) 0   (0) 0.497 
      II 169 (39.4) 122 (72.2) 47   (27.8)  264 (47.0) 248 (93.9) 16 (6.1)  
      III 126 (29.4) 97   (77.0) 29   (23.0)  205 (36.5) 191 (93.2) 14 (6.8)  
      IV 61   (14.2) 50   (82.0) 11   (18.0)  60   (10.7) 56   (93.3) 4   (6.7)  
MSI status           
     MSS/MSI-low 323 (81.2) 253 (78.3) 70   (21.7) 0.005 444 (85.5) 424 (95.5) 20 (4.5) 0.029 
     MSI-high 75   (18.8) 47   (62.7) 28   (37.3)  75   (14.5) 67   (89.3) 8   (10.7)  
CMS subtype           
     CMS1-3 253 (73.3) 219 (86.6) 34   (13.4) < 0.0001 360 (73.9) 351 (97.5) 9   (2.5) < 0.0001 
     CMS4 92   (26.7) 41   (44.6) 51   (55.4)  127 (26.1) 107 (84.3) 20 (15.7)  
CRIS subtype           
     CRIS-A/C-E 283 (87.9)  219 (77.4) 64   (22.6) 0.002  488 (86.2)  468 (95.9) 20 (4.1) < 0.0001 
     CRIS-B 39   (12.1) 21   (53.8) 18   (46.2)  78   (13.8) 64   (82.1) 14 (17.9)  
Percentage values are given in parentheses. Association of CSF1R expression with clinical parameters 
was analyzed using chi-square tests. CSF1R low / high status was defined according to Figure 5.1 and 
Figure 5.2 A, respectively. Statistics were calculated with SPSS (IBM). Table and analysis were made 
by Dr. Markus Kaller.  
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Table 2.  
Multiple regression analysis of overall survival in colon cancer cases from two 
independent cohorts 
 TCGA-COAD GSE395823 
Variables overall survival overall survival 
  HR (95% CI) P HR (95% CI) P 
Age ≥ median 2.02 (1.26-3.24) 0.003 2.11 (1.55-2.88) 0.001 
Male vs. Female 1.08 (0.69-1.68) 0.745 0.71 (0.52-0.96) 0.025 
UICC stage 2.27 (1.74-2.96) < 0.0001 2.14 (1.67-2.58) < 0.0001 
MSI status 1.01 (0.55-1.82) 0.985 0.82 (0.49-1.32) 0.392 
CSF1R  high  1.80 (1.10-2.93) 0.018 1.96 (1.18-3.26) 0.009 
 
Cox proportional hazards models were used for multiple regression analyses. Statistics were calculated 
with SPSS (IBM). HR：Hazard Ratio；CI: Confidence interval. Table and analysis were made by Dr. 
Markus Kaller. 
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5.2 CSF1R represents a direct target of miR-34a  
In order to determine whether the up-regulation of CSF1R expression in CRCs may be 
due to the down-regulation of microRNAs that negatively control the CSF1R mRNA, 
we examined the 3’-UTR of CSF1R for the presence of potential seed-matching sites. 
Only three different microRNAs were identified by all five algorithms used here (Figure 
5.8 A): miR-34a and miR-449a share the same, whereas miR-765 has a different seed-
sequence. Since analysis of TCGA revealed that miR-449a and miR-765 expression 
is almost not detectable in CRCs, whereas miR-34a is expressed at a higher level and 
represents a p53 target, we decided to focus miR-34a (Figure 5.8 B).  
 
 
Figure 5.8 
A, Bioinformatics prediction of matching seed sequences in the CSF1R 3’-UTR using 
five different algorithms. 
B, Expression of miR-34a, miR-449a, and miR-765 in CRC patient samples from 
TCGA. 
 
Notably, the miR-34a seed-matching sequence within the CSF1R 3’-UTR is 
highly conserved in other species (Figure 5.9 A). In line with these observations, 
expression of miR-34a showed an inverse correlation with CSF1R and CSF1 in primary 
CRCs (Figure 5.9 B and C).  
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Figure 5.9 
A, Scheme of the miR-34a seed, the seed-matching sequences and its targeted 
mutation in the 3’-UTR of the CSF1R mRNA. The seed and seed-matching sequences 
are high-lighted in grey. Black vertical bars indicate complementarity between the miR-
34a seed and the CSF1R seed-matching sequence. 
B, C, Correlative analysis between miR-34a and the indicated mRNAs in the samples 
of the TCGA collection of rectal adenocarcinomas (READ; n = 166) using the Pearson 
coefficient. 
A:  Figure and analysis were made by Dr. Markus Kaller.  
 
 
However, we did not detect a miR-34a seed-matching site in the CSF1 mRNA 
(data not shown). Ectopic expression of an Doxycycline(Dox)-inducible pri-miR-34a 
allele resulted in a significant down-regulation of CSF1R mRNA levels in four different 
human CRC lines (Figure 5.10 A). Furthermore, ectopic expression of pri-miR-34a in 
mesenchymal-like SW480 cells, which display low expression of endogenous miR-34a, 
also resulted in down-regulation of CSF1R protein expression (Figure 5.10 B).  
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Figure 5.10 
A, qPCR analysis of CSF1R expression in three different colorectal cancer cell lines 
72 hours after induction of pri-miR-34a expression by addition of doxycyclin (Dox). 
B, Western Blot analysis of CSF1R expression after induction of pri-miR-34a in SW480 
cells by addition of Dox for the indicated periods.  
A, B: Figures and analysis were made by Dr. Markus Kaller.  
In panels A, mean values ± SD are provided. (*) P < 0.05 
 
In a dual-reporter assay, ectopic miR-34a significantly repressed the activity of 
a wild-type CSF1R 3’-UTR reporter and also repressed a TPD52 (a known miR-34a 
target) reporter. However, a CSF1R 3’-UTR reporter with mutations in the miR-34a 
seed-matching sequence was refractory to miR-34a (Figure 5.11). Therefore, miR-34a 
directly represses CSF1R expression via a conserved miR-34a seed-matching 
sequence.  
 
Figure 5.11 Dual-reporter assay after transfection with the indicated pre-miR-34a 
oligonucleotides and human CSF1R 3’-UTR reporter constructs. Mean values ± SD 
are provided. (*) P < 0.05. Figure and analysis were made by Dr. Markus Kaller.  
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5.3 p53 represses CSF1R via inducing miR-34a 
Since miR-34a is directly induced by p53, we determined whether p53 activation would 
also repress CSF1R. Indeed, ectopic expression of p53 repressed CSF1R mRNA and 
protein expression in SW480 cells (Figure 5.12 A and B). In addition, p53 activation 
suppressed CSF1 expression (Figure 5.12 A).  
 
 
 
Figure 5.12 
A, B qPCR analysis (A) of the indicated mRNAs and Western blot analysis (B) of 
CSF1R expression 72 hours after induction of ectopic p53 by addition of Dox to 
SW480/pRTR-p53-VSV cells. B: Figure and analysis were made by Dr. Markus Kaller. 
In panels A, mean values ± SD are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 
0.001. 
 
Furthermore, the repression of CSF1R by p53 was alleviated by inactivation of 
miR-34a via treatment with miR-34a-specific antagomirs, demonstrating that miR-34a 
mediates the repression of CSF1R by ectopic p53 (Figure 5.13 A). In addition, 
treatment with the DNA damaging agents etoposide or 5-FU caused the down-
regulation of CSF1R protein expression in p53+/+, but not in isogenic p53-/- RKO cells 
A B
pri
-m
iR3
4a
CS
F1
R
CS
F1
SW480/pRTR-p53-VSV
- Dox
+Dox
CSF1R
α-tubulin
0 24 48 72 hours + Dox
p53-VSV
SW480/pRTR-p53-VSV
170
55
50
(kDa)
                                                                                                                            Results   
 
60 
 
(Figure 5.13 B). Moreover, the repression of CSF1R by activation of endogenous p53 
by treatment with etoposide was prevented by miR-34a-specific antagomirs (Figure 
5.13 C).  
 
 
Figure 5.13 
A, qPCR (left) and Western blot (right) analysis of SW480/pRTR-p53-VSV cells 
transfected with antago-miR-34a or  control oligonucleotides for 24 hours and/or 
subsequently treated with Dox for 48 hours. 
B, Western blot analysis of CSF1R expression in RKO p53+/+ and RKO p53-/- cells after 
addition of etoposide (20 µM) or 5-FU (25 µg/mL) for the indicated periods.  
C, Western blot analysis of CSF1R proteins in RKO p53+/+ cells transfected with 
antagomir-miR-34a or antagomir control oligonucleotides for 24 hours and subsequent 
exposure to etoposide (20 µM) for 48 hours or DMSO.  
In panels A mean values ± SD are provided. (*) P < 0.05, and (**) P < 0.01. 
 
Taken together, these results show that p53 activation leads to a miR-34a-
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5.4 Coherent feed-forward regulation of CSF1R by SNAIL and miR-34a 
Since CSF1R expression was elevated in CRCs classified as CRIS-B subtype, which 
is characterized by a mesenchymal expression profile, we determined whether CSF1R 
expression is associated with EMT-specific gene expression profiles. Gene Set 
Enrichment Analyses (GSEA) showed that CSF1R mRNA expression is strongly 
associated with the expression of EMT-specific signature mRNAs represented by the 
EMT hallmark gene set (Liberzon et al., 2015) in PDX samples (Figure 5.14 A). A 
similar correlation was found in the TCGA-COAD cohort and the additional cohort 
containing 566 CRC samples (Figure 5.14 B and C). More specifically, CSF1R mRNA 
expression was positively associated with the expression of “canonical” EMT-TFs, 
such as SNAIL and SLUG, and mesenchymal markers such as Vimentin (VIM), 
whereas it displayed an inverse correlation with E-Cadherin (CDH1) (Figure 5.14 D, E 
and F). 
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Figure 5.14 
A, B, C, Genes were preranked by expression correlation coefficient (Pearson r) with 
CSF1R in descending order from left (positive correlation) to right (negative correlation) 
based on RNA expression data obtained from GSE76402 (A), TCGA-COAD (B) and 
GSE39582 (C) and association of EMT_hallmark genes with CSF1R expression was 
subsequently analyzed by GSEA. Pos. corr.: positive correlation, neg. corr.: negative 
correlation. NES: normalized enrichment score. 
D, E, F, Heat-map depicting a hierarchically clustered correlation matrix of pairwise 
expression correlation coefficients (Pearson r) between previously described direct 
miR-34a target genes, EMT markers and CSF1R mRNA.  
D, E, and F: Figures and analysis were made by Dr. Markus Kaller.  
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A
D E F
B
Hallmark_EMT (MSigDB)
PDX (n=529)
NES:3.05
Nom. p-value < 0.0001 Nom.p-value : < 0.001
NES: 2.16
TCGA (n=461)
Nom.p-value : < 0.001
NES: 2.7695456
Hallmark_EMT (MSigDB)
GSE39582 (n=566)C
CSF1R
SNAI2
SNAI1
AXL
CSF1
FN1
ZEB1
ZEB2
VIM
TWIST1
CDH1
PDX (n=529)
Pearson r
-0.50 10
Pearson r
-0.50 10
SNAI1
ZEB1
SNAI2
AXL
VIM
TWIST1
FN1
ZEB2
CSF1
CSF1R
CDH1
TCGA (n=461)
S
N
A
I1
C
S
F1
C
S
F1
R
S
N
A
I2
A
X
L
V
IM
ZE
B
1
ZE
B
2
TW
IS
T1
FN
1
C
D
H
1
SNAI1
CSF1
CSF1R
SNAI2
AXL
VIM
ZEB1
ZEB2
TWIST1
FN1
CDH1
GSE39582 (n=566)
Pearson r
-0.50 10
                                                                                                                            Results   
 
63 
 
presumably lead to induction of CSF1R. Therefore, we determined CSF1R expression 
levels after ectopic expression of SNAIL or SLUG in epithelial-like DLD1 cell pools 
harbouring Dox-inducible expression vectors encoding either SNAIL or SLUG. Indeed, 
CSF1R mRNA showed robust induction concomitantly with repression of pri-miR-34a 
transcription after ectopic expression of SNAIL or SLUG in DLD1 cells (Figure 5.15 A). 
Consistent with previous reports (Siemens et al., 2011), pri-miR-200c was also 
repressed by SNAIL or SLUG. The up-regulation of CSF1R mRNA after activation of 
SNAIL or SLUG was accompanied by an increase in CSF1R protein levels (Figure 5.15 
B).  
 
Figure 5.15 
A, qPCR analysis of the indicated mRNAs 72 hours after addition of Dox to 
DLD1/pRTR-SNAIL-VSV cells (left) and DLD1/pRTR-SLUG-VSV cells (right). 
B, Western blot analysis of CSF1R expression after addition of Dox for the indicated 
periods in DLD1/pRTR-SNAIL-VSV cells (left) and DLD1/pRTR-SLUG-VSV cells 
(right). 
A, B: Figures and analysis were made by Dr. Markus Kaller.  
In panels A mean values ± SD are provided. (*) P < 0.05 and (**) P < 0.01. 
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Although repression of miR-34a by SNAIL is presumably a critical component 
in the regulation of CSF1R, we asked whether direct activation by these EMT-TFs may 
also contribute to the induction of CSF1R expression. Indeed, we detected SNAIL 
occupancy in the first intron of CSF1R in a genome-wide ChIP-Seq analysis of DLD-1 
cells (Figure 5.16 A), suggesting that CSF1R is also directly regulated by SNAIL. 
Accordingly, we identified a cluster of three closely spaced SNAIL binding sites with 
the sequence 5’-[CACCTG]-3’ within the first intron of the CSF1R gene (Figure 5.16 
B). By quantitative chromatin immunoprecipitation (qChIP) of this region, SNAIL 
occupancy at the first intron of the CSF1R gene was confirmed (Figure 5.16 C).  
 
 
Figure 5.16 
A, SNAIL-VSV-derived ChIP-Seq results were obtained after induction of ectopic 
SNAIL in DLD-1 cells and displayed using the UCSC genome browser. 
B, Scheme of the first intron of human CSF1R. Putative SNAIL binding sites are 
indicated as bold letters in the DNA sequence. Small arrows indicate the amplicon 
used in Figure 5.16 C for qChIP analysis. 
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C, ChIP analysis of SNAIL occupancy at the first intron of CSF1R and promoter of miR-
200c 24h after addition of Dox or cells left untreated using anti-VSV and anti-rabbit-
IgG antibodies. AchR served as negative control. 
A：Figure and analysis were made by Dr. Markus Kaller.  
In panels A and B mean values ± SD are provided. (*) P < 0.05 and (**) P < 0.01. 
 
 
Moreover, siRNA-mediated suppression of CSF1R in SNAIL-expressing DLD1 
cells resulted in a decrease in invasion (Figure 5.17). Taken together, these results 
demonstrate a coherent feed-forward regulation of CSF1R expression by SNAIL and 
miR-34a. In addition, CSF1R may be a critical downstream mediator of SNAIL-induced 
invasion in CRC cell lines.  
 
Figure 5.17 
Boyden-chamber invasion assay of DLD1/pRTR-SNAIL-VSV cells after the indicated 
treatments. Mean values ± SD are provided. (*) P < 0.05.  
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5.5 Repression of miR-34a after CSF1R activation is mediated by STAT3 
We have previously found that miR-34a often forms double-negative feed-back 
loops with its targets (Hahn et al., 2013; Liberzon et al., 2015; Rokavec, Oner, et al., 
2014; Siemens et al., 2011). Also here we observed a downregulation of pri-miR-34a 
expression after activation of its target CSF1R either by CSF1 or IL34 (Figure 5.18 A). 
Also after ectopic expression of a constitutively active form of CSF1R, which was 
generated previously by changing lysine at position 301 to serine (Roussel, Downing, 
Rettenmier, & Sherr, 1988), the expression of pri-miR-34a was down-regulated in DLD-
1 CRC cells (Figure 5.18 B). Furthermore, inhibition of CSF1R by the small molecule 
inhibitor GW2580 (Bencheikh et al., 2019) resulted in an upregulation of pri-miR-34a 
in SW480 and SW620 cells (Figure 5.18 C and D).  
 
Figure 5.18 
A, qPCR analysis of pri-miR-34a in DLD1/pRTR-CSF1R-FLAG treated with Dox for 96 
hours. The last 72 hours also treated with CSF1 or IL34. 
B, qPCR analysis of pri-miR-34a in DLD1/pRTR-CSF1R_L301S-FLAG after addition 
of Dox for 48 hours. 
C, D, qPCR analysis of indicated mRNAs in SW480 (C) and SW620 (D) cells after 
treatment with GW2580 (1 nM) for 72 hours. 
In panels A, B, C, and D mean values ± SD are provided. (*) P < 0.05 and (**) P < 0.01. 
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Since Gene Set Enrichment Analyses (GSEA) showed a positive correlation 
between CSF1R expression and the IL6_JAK_STAT3 pathway hallmark gene 
signature (Figure 5.6 B, and Figure 5.19 A), we asked whether STAT3 activation may 
mediate the repression of miR-34a after CSF1R activation. Indeed, treatment of DLD-
1 cells ectopically expressing CSF1R with CSF1 resulted in increased phosphorylation 
of STAT3 at residue S727 which indicates STAT3 activation (Figure 5.19 B). Also, the 
ectopic expression of the constitutively active CSF1R_L301S allele resulted in STAT3 
phosphorylation (Figure 5.19 C). Of note, RNAi-mediated down-regulation of STAT3 
significantly reversed the suppression of pri-miR-34a observed after CSF1R activation, 
whereas silencing of SNAIL only led to a minor de-repression (Figure 5.19 D).  
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Figure 5.19 
A, Genes were preranked by expression correlation coefficient (Pearson r) with CSF1R 
in descending order from left (positive correlation) to right (negative correlation) based 
on RNA expression data obtained from TCGA-COAD and analyzed by GSEA. Pos. 
corr.: positive correlation, neg. corr.: negative correlation. NES: normalized enrichment 
score. 
B, Western blot analysis of STAT3 phosphorylation at residue S727 and STAT3 
expression after addition of Dox for 24 hours and subsequent exposure to CSF1 for 
indicated periods in DLD1/pRTR-CSF1R cells. 
C, Western blot analysis of DLD1/pRTR-CSF1R_L301S cells after addition of Dox for 
indicated periods. 
D, qPCR analysis of pri-miR-34a expression. DLD1/pRTR-CSF1R cells were 
transfected with indicated siRNAs. After 6 hours they were treated with Dox and CSF1 
for 48 hours. The STAT3- and SNAIL-specific siRNAs used here have been validated 
previously (Rokavec, Oner, et al., 2014). 
In panels D mean values ± SD are provided. (**) P < 0.01. 
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Therefore, the down-regulation of miR-34a by CSF1R is, at least in part, 
mediated by STAT3 activation. This effect is presumably mediated via a conserved 
STAT3-binding site in the miR-34a promoter, which we have characterized previously 
(Rokavec, Oner, et al., 2014). Taken together, miR-34a, CSF1R and STAT3 therefore 
form a double-negative feed-back loop. In combination with the coherent feed-forward 
loop described above these regulatory circuitries may allow cells to integrate 
antagonistic mitogenic (CSF1, WNT) and anti-proliferative (p53) signals (see model in 
Figure 5.20). 
 
 
Figure 5.20 
Model of the regulations characterized in Figures 5.8-5.19. The dashed line separates 
p53 on (right) and p53 off states (left).  
 
 
5.6 CSF1R activation induces EMT, migration, and invasion 
Next, we asked whether CSF1R activation is sufficient to induce EMT. Therefore, 
we treated the epithelial-like CRC cell line HCT15 with CSF1 or IL-34 for 72 hours. 
Indeed, CSF1 and IL-34 induced the transition from an epithelial morphology with 
dense islands of cobblestone-shaped cells to a mesenchymal morphology with 
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spindle-shaped cells forming protrusions and displaying a scattered growth pattern 
(Figure 5.21 A). In addition, mesenchymal markers, such as Vimentin (VIM), SNAIL, 
and ZEB1, were induced on mRNA and protein levels, while CDH1 protein expression 
decreased (Figure 5.21 B and C).  
 
 
Figure 5.21 
A, Representative phase-contrast pictures of HCT15 cells after treatment with IL34 or 
CSF1 for 72 hours. Scale bar: 25 µm.  
B, qPCR analysis of the indicated EMT markers after treatment of HCT15 cells with 
IL34 or CSF1 for 48 hours. 
C, Western blot analysis of indicated EMT markers after treatment of HCT15 cells with 
IL34 or CSF1 for 72 hours. 
In panels B mean values ± SD are provided. (*) P < 0.05. 
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mediated by protein-tyrosine phosphatase ζ (PTP-ζ), which represents an alternative 
IL34 receptor (Nandi et al., 2013).  
 
 
Figure 5.22 
Western blot analysis of HCT15 transfected with siRNA CSF1R or siRNA Control 
oligonucleotide for 24 hours and/or subsequently treated with IL34 for 72 hours. 
 
 
However, treatment of DLD1 CRC cells with CSF1 or IL34 did not significantly 
affect the expression of epithelial or mesenchymal markers (Figure 5.23 A). This non-
responsiveness is presumably due to the relatively low expression of CSF1R protein 
in DLD1 cells when compared to HCT15 cells (Figure 5.23 B). Indeed, ectopic CSF1R 
expression in DLD1 cells restored their responsiveness to CSF1, as CSF1 induced the 
hallmarks of EMT in these cells (Figure 5.23 C, D, E, F and G). Taken together, these 
results demonstrate that CSF1R activation induces EMT in CRC cells. 
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Figure 5.23 
A, qPCR analysis of DLD1 cells after treatment with CSF1 or IL34 for 48 hours. 
B, Western blot analysis of CSF1R expression in DLD1 and HCT15 cells. 
C, Flow cytometric determination of the frequency of cells with inducible expression of 
eGFP in DLD-1 cell pools harboring a pRTR-CSF1R vector after addition of 100 ng/ml 
Dox for 72 hours.  
D, Western blot analysis of CSF1R expression in DLD1/ pRTR-CSF1R cells after 
addition of 100 ng/ml Dox for 72 hours.  
E, Representative phase-contrast pictures of DLD1/pRTR-CSF1R cells after treatment 
with Dox for 24 hours, and then exposed to CSF1 for 72 hours. Scale bar: 25 µm.  
F, qPCR analysis of DLD1/pRTR-CSF1R-FLAG cells that were treated with Dox for 24 
hours and then exposed to CSF1 or IL34 for another 48 hours.   
G, Western blot analysis of DLD1/pRTR-CSF1R-FLAG cells treated with Dox for 24 
hours and subsequently exposed to CSF1 for the indicated periods. 
In panels A and F mean values ± SD are provided. (*) P < 0.05. 
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   Expression of CSF1R was associated with epithelial cell migration by GSEA 
analysis (Figure 5.24).  
 
Figure 5.24 
Genes were preranked by expression correlation coefficient (Pearson r) with CSF1R 
in descending order from left (positive correlation) to right (negative correlation) based 
on RNA expression data and association of indicated gene signature with CSF1R 
expression was subsequently analyzed by GSEA. Pos. corr.: positive correlation, neg. 
corr.: negative correlation. NES: normalized enrichment score. 
 
Therefore, we asked whether activation of CSF1R enhances cell migration, 
invasion and eventually metastases formation, as these processes are functional 
consequences of an EMT. Indeed, activation of CSF1R accelerated the closure of a 
scratch in CSF1R-expressing DLD1 cells (Figure 5.25 A). In addition, migration and 
invasion were enhanced after CSF1R activation as determined in a Boyden-chamber 
assay, whereas treatment with the CSF1R inhibitors GW2580 or BLZ925 resulted in a 
significant decrease of cellular invasion in the mesenchymal-like cell line SW620 
(Figure 5.25 B, C and D).  
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Figure 5.25 
A, Scratch assay of DLD1-pRTR-CSF1R cells treated with Dox or Dox/CSF1. Scale 
bar: 200 µm. 
B, C, Boyden-chamber assays of cellular migration (B) or invasion (C). 
D, SW620 cells were pre-treated with inhibitors as indicated, and subsequently treated 
with Dox and CSF1. After incubation with CSF1 or 48 hours, cells were subjected to 
Boyden-chamber assay. 
In panels A, B, C and D mean values ± SD are provided. (*) P < 0.05, (**) P < 0.01, 
and (***) P < 0.001. 
 
 
Furthermore, ectopic expression of a miR-34a-resistant CSF1R cDNA in the 
mesenchymal-like cell line SW480 prevented the repression of migration and invasion 
by pre-miR-34a (Figure 5.26 A and B). Therefore, the repression of CSF1R by miR-
34a is presumably required for inhibition of migration and invasion by miR-34a. 
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Figure 5.26 
A, B, Cells were transfected with or without pre-miR-34a oligo one day before the 
addition of Dox and CSF1, and then subjected to the migration (A) or invasion assay 
(B). In panels A and B mean values ± SD are provided. (*) P < 0.05, (**) P < 0.01, and 
(***) P < 0.001. 
 
 
Next, DLD-1 cells harbouring a luciferase marker gene and an inducible CSF1R 
allele were injected into mice to assess the effect of CSF1R activation on lung 
metastases formation. Indeed, only cells with activated CSF1R formed lung 
metastases in mice as evidenced by a significant increase in luciferase signal by week 
5 which further increased until week 7 (Figure 5.27 A and B).  
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Figure 5.27 
A, DLD1-Luc2/pRTR-CSF1R-FLAG cells treated with or without Dox and CSF1 were 
injected into the tail vein of NOD/SCID mice. At the indicated time points, 
bioluminescence signals were recorded. Bioluminescence signals are presented as 
“total flux”.  
B, Representative examples of bioluminescence imaging at the indicated time points 
after tail vein injection of DLD1-Luc2/pRTR-CSF1R cells. 
A, B: Figures and analysis were made by Dr. Matjaz Rokavec.  
In panels A mean values ± SD are provided. (*) P < 0.05. 
 
 
In SW620 CRC cells down-regulation of CSF1R expression by transfection with 
CSF1R-specific siRNAs or pre-miR-34a inhibited invasion as determined in a Boyden-
chamber assay (Figure 5.28 A). When SW620 cells treated similarly were injected into 
the tail veins of mice, a reduced number of metastatic tumor nodules were detected in 
the lungs 8 weeks later (Figure 5.28 B and C). The stronger inhibitory effect of pre-
miR-34a oligonucleotides, as compared to CSF1R-specific siRNAs, can be explained 
by the inhibition of other miR-34a targets, which promote the formation of metastases, 
such as the IL6R (Rokavec, Oner, et al., 2014).  
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Figure 5.28 
A, SW620 cells were transfected with the indicated oligonucleotides for 48 hours and 
then subjected to an invasion assay in Boyden-chambers for another 36 hours.  
B, SW620 cells were transfected as the indicated oligonucleotides for 48 hours and 
subsequently injected into the tail vein of NOD/SCID mice. Left, lungs were resected 8 
weeks after injection. Arrows, metastatic tumor nodules. Right, representative 
examples of the H&E staining of the resected lungs are shown. Scale bar, 200 µm. 
C, Quantification of metastatic tumor nodules in the lung per mouse 8 weeks after tail-
vein injection.  
B: Xenograft experiments were performed by Dr. Matjaz Rokavec.  
In panels A and C mean values ± SD are provided. (*) P < 0.05, (***) P < 0.001, and 
(****) P < 0.0001. 
 
 
 Taken together, these results show that CSF1R activation is sufficient and 
necessary for invasion and metastases formation of CRC cells. 
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5.7 CSF1R mediates resistance to 5-FU in CRC cells 
Since CSF1R activation induced EMT, which has been linked to chemo-resistance 
(Sale et al., 2019), we determined whether CSF1R activity and/or expression 
influences the sensitivity of CRC cells to the chemo-therapeutic agent 5-FU (5-fluoro-
uracil), which is commonly used in CRC therapy. DLD-1 cells ectopically expressing 
CSF1R were treated with CSF1 for 24 hours and subsequently exposed to 5-FU for 3 
days. Cells expressing ectopic CSF1R formed more colonies and were therefore less 
sensitive to 5-FU, when compared to control cells (Figure 5.29).  
 
Figure 5.29 
For a colony formation assay 500 cells were seeded per well of a 6-well plate and 
cultivated with or without Dox for 24 hours, then exposed to CSF1 for another 24 hours, 
and then treated with 5-FU for 72 hours. Subsequently, cells were fixed and stained 
with crystal violet. Quantification of colony formation (right) and representative 
examples of crystal violet staining (left). Mean values ± SD are provided. (*) P < 0.05, 
and (**) P < 0.01. 
 
 
The addition of CSF1 further increased the number of colonies formed by cells 
ectopically expressing CSF1R. Next, we established a 5-FU-resistant cell pool 
(DLD1_5FU) by exposing DLD-1 cells to increasing concentrations of 5-FU over a 
period of five months. The tolerance of DLD1_5FU cells to 5-FU was significantly 
DLD1/pRTR-CSF1R (+ 5-FU)
0
50
100
150
C
ol
on
y
nu
m
be
r
Control +Dox +Dox/CSF1
Control +Dox +Dox/CSF1
**
*
                                                                                                                            Results   
 
79 
 
higher than that of parental DLD1 cells (DLD1_par) (Figure 5.30 A and B). The IC50 
value of 5-FU for DLD1_5FU cells was 8-fold increased when compared to the parental 
cells. Accordingly, DLD1_5FU cells exposed to 5-FU underwent less apoptosis than 
DLD1_par cells (Figure 5.30 C).  
 
Figure 5.30 
A, The indicated cell pools were treated with 5-FU for 48 hours and subsequently 
subjected to MTT assay. Micrographs show cell pools with formation of MTT formazan, 
which is directly proportional to the number of living cells Scale bars represent 200 µm. 
B, IC50 determination of DLD1_par and DLD1_5FU cells in response to 5-FU. Cells 
were treated with the indicated concentrations of 5-FU for 48 hours and then subjected 
to an MTT assay. 
C, Detection of apoptotic cells by Annexin V-FITC and PI staining after treatment with 
5-FU for 36 hours. 
In panels C mean values ± SD are provided. (*) P < 0.05 and (**) P < 0.01. 
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Interestingly, CSF1R expression was up-regulated concomitantly with down-
regulation of miR-34a in DLD1_5FU cells when compared to DLD1_par cells (Figure 
5.31 A and B). Similar results were obtained with HT29 cells, that were rendered 
resistant to 5-FU as described for above for DLD-1 cells (Figure 5.31 C).  
 
Figure 5.31 
A, B, qPCR analysis of CSF1R (A) and pri-miR34a (B) expression in DLD1_par and 
DLD1_5FU cells. 
C, Detection of pri-miR-34a and CSF1R expression in HT29_par and HT29_5FU cells. 
In panels A, B and C mean values ± SD are provided. (*) P < 0.05, (**) P < 0.01 and 
(***) P < 0.001 
 
Furthermore, GSEA showed that increased CSF1R is negatively associated 
with apoptosis related gene expression (Figure 5.32 A). In addition, down-regulation of 
CSF1R in DLD_FU cells by specific siRNA pools resulted in decreased cell viability 
after 5-FU treatment (Figure 5.32 B) and was accompanied by an increase in apoptosis 
(Figure 5.32 C and D). Interestingly, ectopic expression of pre-miR-34a further 
enhanced apoptosis, indicating that miR-34a may target additional suppressors of 
apoptosis besides CSF1R in this context.  
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Figure 5.32 
A, Genes were preranked by expression correlation coefficient (Pearson r) with CSF1R 
in descending order from left (positive correlation) to right (negative correlation) based 
on RNA expression data, and association of the indicated gene signatures with CSF1R 
expression was analyzed by GSEA. Pos. corr.: positive correlation, neg. corr.: negative 
correlation. NES: normalized enrichment score. 
B, DLD1_5FU cells were transfected with control or CSF1R-specific siRNAs for 24 
hours and subsequently treated with increasing concentrations of 5-FU for 48 hours. 
Then the IC50 was determined by an MTT assay. 
C, D, DLD1_5FU cells were transfected with indicated oligonucleotides, subsequently 
treated with 5-FU for 36 hours and apoptotic cells were detected by Annexin V-FITC 
and PI staining.  
In panels A, D, E, F, G and J mean values ± SD are provided. (*) P < 0.05, (**) P < 
0.01 and (***) P < 0.001 
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Taken together, down-regulation of miR-34a and elevated expression of CSF1R 
is selected for during treatment with 5-FU and confers resistance of CRC cells to 5-FU. 
 
5.8 CSF1R mediates EMT, migration, and invasion of 5-FU in CRC cells 
Unlike parental DLD1 cells, DLD1_5FU cells displayed a mesenchymal-like 
morphology (Figure 5.33).  
 
 
Figure 5.33 
Representative phase-contrast pictures of DLD1_par and DLD1_5FU cells. Scale 
bars represent 25 µm. 
 
 
Additionally, VIM, SNAIL and ZEB1 were upregulated at the mRNA and protein 
levels in DLD1_5FU cells when compared to the parental DLD-1 cells (Figure 5.34, A 
and B). On the contrary, E-cadherin protein expression was decreased in DLD1_5FU 
cells. In addition to CSF1R other target mRNAs of miR-34a, such as AXL, PDGFR, c-
Met, c-Kit, ZNF281 and CD44, were up-regulated in DLD1_5FU cells. Consistent with 
the increased stemness known to be associated with EMT (Mani et al., 2008), the 
stemness markers CD44, CD166, BMI1 and CD24 were upregulated in DLD1_5FU 
cells.  
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Figure 5.34 
A, Western blot analysis of indicated proteins. 
B, qPCR analysis of indicated mRNA. 
In panels B mean values ± SD are provided. (*) P < 0.05, and (**) P < 0.01. 
 
In line with a passage through an EMT, migration and invasion was significantly 
elevated in DLD1_5FU cells when compared to DLD1_par cells (Figure 5.35 A). 
Furthermore, ectopic expression of pri-miR-34a reduced VIM and SNAIL expression, 
and significantly inhibited migration and invasion in DLD1_5FU cells (Figure 5.35 B 
and C).  
 
Figure 5.35 
A, Analysis of relative invasion and migration using Boyden-chamber assays. 
B, Western blot analysis of indicated proteins in DLD1_5FU/pRTR-miR34a cells after 
treatment with or without Dox for 72 hours. 
C, Relative invasion and migration of DLD1_5FU/pRTR-miR34a cells after treatment 
with or without Dox for 72 hours. 
In panels A and C mean values ± SD are provided. (**) P < 0.01. 
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Notably, down-regulation of CSF1R expression by specific siRNAs inhibited 
migration and invasion in DLD1_5FU cells to a similar extent as ectopic pri-miR-34a 
expression (Figure 5.36 A). Also, HT29_5FU cells displayed increased migration and 
invasion, which was repressed by CSF1R-specific siRNA or pre-miR-34a (Figure 5.36 
B, C and D).  
 
 
 
Figure 5.36 
A, DLD1_5FU cells were transfected with control or CSF1R-specific siRNAs for 24 
hours and then subjected to migration and invasion assays for another 36 hours. 
Subsequently, cells were fixed and stained with crystal violet. 
B, Relative invasion and migration of HT29_par and HT29_5FU. 
C, D, HT29_5FU cells were transfected with siRNA or pre-miR-34a oligo for 24 hours 
and then subjected to migration and invasion assays for another 36 hours. 
In panels A, B, C, and D mean values ± SD are provided. (*) P < 0.05, (**) P < 0.01 
and (***) P < 0.001. 
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Therefore, the enhancement of migration and invasion in 5-FU-resistant CRC 
cells is mediated, at least in part, by downregulation of miR-34a expression and the 
resulting up-regulation of CSF1R expression.  
Treatment of DLD1_5FU cells with GW2580, a specific CSF1R inhibitor, 
suppressed invasion to a large extent as evidenced by a Boyden-chamber assay 
(Figure 5.37 A). Eight weeks after injection of DLD1_5FU cells into the tail vein of 
NOD/SCID mice their lungs displayed an increased number of metastases when 
compared to mice injected with DLD1_par cells (Figure 5.37 B and C). Pre-treatment 
of DLD1_5FU cells with the CSF1R-inhibitor GW2580 before injection suppressed 
metastasis formation in NOD/SCID mice.  
 
Figure 5.37 
A, Cells were treated with or without inhibitor GW2580 for 48 hours and then subjected 
to an invasion assay in Boyden-chambers containing Matrigel for another 36 hours. 
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B, Left, lungs were resected 8 weeks after injection. Arrows, metastatic tumor 
nodules. Right, representative examples of the H&E staining of the resected lungs 
are shown. Scale bar, 200 µm. 
C, Quantification of metastatic tumor nodules in the lung per mouse 8 weeks after tail-
vein injection. Cells were treated as indicated for 48 hours and subsequently injected 
into the tail vein of NOD/SCID mice.  
B: Xenograft experiments were performed by Dr. Matjaz Rokavec.  
In panels A and C mean values ± SD are provided. (*) P < 0.05, (**) P < 0.01 and (***) 
P < 0.001. 
Taken together, these results show that elevated CSF1R expression promotes 
metastases formation of chemo-resistant CRC cells.  
 
5.9 Epigenetic silencing of miR-34a contributes to CSF1R up-regulation, 5-FU 
resistance and CRC progression 
We have previously shown that methylation of the CpG island upstream of the miR-
34a transcriptional start site (TSS) results in silencing of miR-34a expression (Lodygin 
et al., 2008). Therefore, we analyzed whether the down-regulation of miR-34a 
expression observed in DLD1_5FU cells is due to methylation of the miR-34a promoter. 
Whereas DLD1_par cells harboured both methylated and non-methylated miR-34a 
alleles as detected by MSP (methylation-specific PCR), DLD-1_5FU cells only 
displayed methylated miR-34a promoter alleles (Figure 5.38 A and B). In HT29_par 
cells only non-methylated miR-34a was detected, whereas HT29_5FU cells also 
showed methylated besides non-methylated miR-34a alleles. As reported previously, 
MiaPaCa2 pancreatic cancer cells displayed methylated and un-methylated miR-34a 
alleles (Lodygin et al., 2008). In addition, we performed a bisulfite sequencing analysis 
of the miR-34a promoter region as described before (Lodygin et al., 2008). Overall 
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methylation of the miR-34a promoter was significantly higher in DLD1_5FU than in 
DLD1_par cells (Figure 5.38 C).  
 
 
 
Figure 5.38 
A, Genomic region 2.0 kbp upstream of the transcriptional start site (TSS, position 
indicated by arrow) within the human miR-34a gene. Vertical bars represent CpG-
dinucleotides. The position of the p53 binding site (BDS) is indicated. The horizontal 
bars indicate PCR amplicons used for methylation-specific PCR (MSP) and bisulfite 
sequencing (BSP), respectively. 
B, Representative results of methylation-specific PCR (MSP) analysis. M, methylation-
specific PCR-product; U, un-methylated allele spec. PCR-product; Untreated: no 
bisulfite added; PCR dH2O, no DNA in PCR; bisulfite dH2O, no DNA input in bisulfite 
reaction; HT29, negative control; MiaPaCa2, positive control. 
C, Bisulfite sequencing analysis of the miR-34a promoter in DLD1_par and DLD1_5FU 
cells. 9 subcloned amplification products were sequenced for each cell lines. Each 
horizontal line represents one individual clone, and each circle one single CpG 
dinucleotide. Open circles represent non-methylated and black circles methylated 
CpGs.  
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Furthermore, DLD1_5FU cells were treated with 5-aza-2'deoxycytidine (5-aza) 
and/or Trichostatin A (TSA), which are inhibitors of DNA methyl-transferases and 
histone deacetylases, respectively, in order to reactivate the expression of miR-34a 
silenced by CpG methylation. Pri-miR-34a was re-expressed after treatment of 
DLD1_5FU cells with 5-aza and further increased by the combined treatment with 5-
aza and TSA (Figure 5.39 A). On the contrary, CSF1R expression was downregulated 
after treatment with 5-aza or the combination of 5-aza and TSA (Figure 5.39 B). 
Therefore, hyper-methylation of the miR-34a promoter decreased the expression of 
miR-34a and thereby presumably caused the up-regulation of CSF1R expression in 5-
FU resistant cells.  
 
 
Figure 5.39 
A, qPCR analysis of pri-miR-34a in DLD1_5FU cells after treatment with 5-aza for 72 
hours or alternatively with 5-aza for 72 hours combined with TSA for the last 24 hours. 
B, Western blot analysis of cell lysates isolated from DLD1_5FU cells after treatment 
with 5-aza for 72 hours or alternatively with 5-aza for 72 hours combined with TSA for 
the last 24 hours. 
In panels A mean values ± SD are provided. (*) P < 0.05. 
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expression of CSF1R protein was analyzed by immunohistochemistry in 90 CRC 
samples, for which the methylation status of miR-34a had been determined previously 
(Hahn et al., 2013). Notably, in CRCs with high miR-34a CPG methylation the 
expression of CSF1R protein was significantly higher than in CRCs with decreased 
miR-34a CpG methylation (Figure 5.40 A and B).  
 
Figure 5.40 
A, Immunohistochemistry score for CSF1R. The staining intensity score is 0 for absent, 
1 for low, 2 for intermediate and 3 for strong signal. Representative examples are 
shown.  
B, Left: Quantification of CSF1R protein expression in human CRC samples of 78 
patients (left). The methylation status of miR-34a in these samples had been 
determined previously (Siemens, Neumann, et al., 2013). Right: Representative 
immunohistochemical detections of CSF1R protein in miR-34a mCPG low and high 
tumors, respectively. Scale bar: 50 μm. 
A, B: IHC was made by Professor Dr. David Horst. 
 
 
Furthermore, CSF1R expression was elevated at the infiltrative tumor edge of 
primary CRCs that were accompanied by liver metastases (M1 tumors) when 
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compared to primary CRCs without liver metastases (M0; Figure 5.41). Therefore, the 
inverse correlation between miR-34a CpG-methylation and CSF1R expression was 
also found in primary CRCs. Furthermore, increased expression of CSF1R at the 
invasion front of primary CRCs was associated with distant metastasis.  
 
 
Figure 5.41 
Evaluation of CSF1R protein expression at the invasion front in M0 and M1 CRCs (left 
chart) and examples of representative immunohistochemical detections (right panel). 
The presence of an invasion front was confirmed by DH, a certified pathologist. Results 
were analyzed using the chi-square test. Scale bar: 50 μm. IHC was made by Professor 
Dr. David Horst. 
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6. Discussion 
Our results suggest that the reciprocal regulation between miR-34a and CSF1R 
controls EMT and chemo-sensitivity. The deregulation of this feedback loop during 
CRC progression may contribute to metastasis and chemo-resistance (see also the 
graphical abstract Figure 6.1). Since CSF1R is expressed at elevated levels in several 
types of tumors (Cioce et al., 2014; J. Menke et al., 2012; Patsialou et al., 2015), the 
regulations identified here may also be relevant to other entities. Not only CSF1R, but 
also its ligands CSF1 and IL34, are expressed at elevated levels in CRCs (Dang et al., 
2016; Franze et al., 2018a; Mroczko et al., 2003). In the human colon expression of 
CSF1 is significantly higher than that of IL34, suggesting CSF1 is the main ligand for 
activation of CSF1R in CRC (Zwicker et al., 2015). Here, analysis of TCGA datasets 
and two additional cohorts of CRC patients showed that elevated mRNA levels of 
CSF1R, CSF1 and IL34 are associated with poor survival of CRC patients. The 
analysis of patient-derived xenografts (PDXs) and single cell sequencing data revealed 
tumor cell intrinsic expression of CSF1R. We determined that miR-34a directly targets 
CSF1R mRNA and thereby mediates the repression of CSF1R by p53. This is in line 
with a previous study that showed that a miR-34a mimic downregulates csf1r mRNA 
expression in rats (Chen et al., 2016). However, the authors did not provide evidence 
for a direct regulation nor did they study the miR-34a/CSF1R connection further. Since 
CSF1R represents a direct target of miR-34a, the elevated expression of CSF1R in 
CRCs may result from the epigenetic silencing of miR-34a, which frequently occurs in 
CRC (Lodygin et al., 2008; Vogt et al., 2011). Interestingly, ectopic expression of p53 
not only repressed CSF1R via miR-34a, but also its ligand CSF1. The latter effect may 
be due to the induction of the microRNAs miR-148b and miR-1207 by p53, since both 
microRNAs are directly induced by p53 and target CSF1 mRNA (Cimino et al., 2013; 
                                                                                                                      Discussion   
 
92 
 
Dang et al., 2016). Interestingly, a recent study showed that p53 deletion results in 
secretion of CSF1 in a pancreatic tumor model and was suggested to influence stromal 
cells, such as tumor-associated macrophages (Blagih et al., 2020). Our results suggest 
that the increased CSF1 secretion resulting from p53 inactivation/mutation may 
cooperate with increased CSF1R expression in a tumor cell autonomous manner.   
 
 
Figure 6.1  
Summarizing model of the regulatory loops characterized here and their alterations 
during colorectal cancer progression. The thickness of the lines and arrows 
corresponds to the relative degrees of the indicated inhibitions and activations of 
expression. 
 
Here we show that CSF1R is directly and indirectly induced by SNAIL in a 
coherent feed-forward loop, which involves the down-regulation of its repressor miR-
34a by SNAIL (see also scheme in Figure 5.20). The regulatory circuit characterized 
here also involves STAT3, which is activated by CSF1R and itself represses miR-34a. 
We have previously reported, that miR-34a is repressed directly by STAT3, which 
contributes to IL6-induced EMT and invasion in CRCs and colitis-associated colon 
cancer (Rokavec, Oner, et al., 2014). Besides mediating SNAIL-induced invasion, 
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activation of CSF1R by CSF1 or IL34 induced EMT in CRC cell lines which was 
associated with increased migration, invasion and lung metastases formation in a 
xenograft mouse model. The induction of EMT by CSF1R presumably induces a 
mesenchymal state in primary CRCs which allows invasion, intravasation, and 
extravasation during metastatic spread. Interestingly, CSF2/GM-CSF has recently 
been shown to induce EMT in colon cancer cells and may thereby contribute to CRC 
progression as well (Chen et al., 2017).  
5-FU-based chemotherapy represents the most common chemotherapeutic 
regime for CRC patients with metastatic tumors (Tong et al., 2016). However, long-
term use of 5-FU usually results in drug resistance, which is a major cause of 
therapeutic failure (Housman et al., 2014). Here we describe the establishment of 5-
FU-resistant CRC cell lines that display increased mesenchymal characteristics when 
compared to the parental cell lines. We found that downregulation of miR-34a and 
increased expression of CSF1R critically contribute to 5-FU resistance. Additional 
targets of miR-34a, such as AXL, PDGFR, c-Met, c-Kit, ZNF281 and CD44, were also 
upregulated in chemo-resistant DLD1 cells, suggesting that the acquisition of chemo-
resistance may involve several additional factors and signaling pathways. Re-
expression of miR-34a or silencing of CSF1R in DLD1_5FU and HT29_5FU cells 
restored the sensitivity to 5-FU, indicating the importance of the dysregulation of miR-
34a and CSF1R in 5-FU resistance. Therefore, inhibiting CSF1R in combination with 
restoring miR-34a function may have therapeutic potential for the treatment of CRC. 
We have previously characterized the RTK c-kit as a miR-34a target and found that its 
down-regulation sensitizes CRC cells to 5-FU (Siemens, Jackstadt, Kaller, & 
Hermeking, 2013). In addition, other RTKs, such as AXL and PDGFR, have been 
characterized as miR-34a targets (Garofalo et al., 2013; Kaller et al., 2011; Silber et 
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al., 2012). Therefore, the repression of RTKs may represent an important mechanism 
of tumor suppression by miR-34a. 
During the establishment of 5-FU-resistant CRC cells, miR-34a expression was 
downregulated as a consequence of CpG methylation of its promoter. This event and 
the resulting up-regulation of CSF1R expression critically contributed to resistance 
towards 5-FU. We have previously shown that the silencing of miR-34a in primary 
tumors is associated with metastasis in CRC patients and in combination with the 
elevated expression of c-Met and β-Catenin predicts a poor outcome (Hahn et al., 
2013). Here, CSF1R was expressed at elevated levels at the invasion front of primary 
CRCs. Therefore, up-regulation of CSF1R expression due to miR-34a silencing may 
promote CRC progression and result in decreased survival of CRC patients. The 
results presented here suggest that targeting the miR-34a/CSF1R pathway might be a 
feasible approach to inhibit CRC metastasis and overcome resistance to 5-FU-based 
therapy. Taken together, targeting CSF1R may not only affect the tumor 
microenvironment and boost immune cells targeting the tumor (15), but may also 
directly inhibit tumor initiation and progression via the mechanisms described here.   
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7. Summary 
The miR-34a gene is a direct target of p53 and is commonly silenced in colorectal 
cancer (CRC). In primary CRCs increased expression of the receptor tyrosine kinase 
colony stimulating factor 1 receptor/CSF1R was associated with a mesenchymal-like 
subtype and poor patient survival, and showed an inverse correlation with miR-34a 
expression, suggesting that it may represent a miR-34a target. Indeed, the 3’-UTR of 
CSF1R contains a miR-34a seed-matching site and CSF1R expression was directly 
inhibited by miR-34a. Furthermore, p53 repressed CSF1R via inducing miR-34a, 
whereas SNAIL and SLUG induced CSF1R both directly and indirectly, via repressing 
miR-34a. Activation of CSF1R inhibited miR-34a via STAT3. CSF1R activation was 
sufficient and required for EMT, migration, invasion and metastases formation of CRC 
cells. Acquired resistance of CRC cells to 5-FU was mediated by CpG-methylation of 
miR-34a and the resulting induction of CSF1R. Both alterations were required for EMT, 
invasion and metastases of 5-FU-resistant CRC cells. In primary CRCs elevated 
expression of CSF1R was detected at the invasion front and was associated with CpG 
methylation of the miR-34a promoter as well as formation of distant metastases. In 
conclusion, the reciprocal regulation of miR-34a and CSF1R identified here controls 
EMT, metastasis and chemo-sensitivity of CRC cells.  
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8. Zusammenfassung 
Das miR-34a-Gen ist ein direktes Ziel von p53 und wird beim Kolorektal-Karzinom 
(KRK) in den meisten Fällen epigenetisch inaktiviert. In primären KRKs war eine 
erhöhte Expression des Rezeptor-Tyrosinkinase-Kolonie-stimulierenden Faktor-1-
Rezeptors / CSF1R mit einem mesenchymalen Subtyp und einem schlechten 
Patientenüberleben assoziiert und zeigte eine inverse Korrelation mit der miR-34a-
Expression, was darauf hindeutet, dass es sich bei der CSF1R mRNA möglicherweise 
um ein miR-34a Ziel handelt. Tatsächlich enthält der 3'-UTR von CSF1R eine miR-
34a-Bindungs-Stelle und die CSF1R-Expression wurde direkt durch miR-34a inhibiert. 
Darüber hinaus unterdrückte p53 CSF1R durch Induktion von miR-34a, während 
SNAIL und SLUG CSF1R sowohl direkt als auch indirekt durch Unterdrückung von 
miR-34a induzierten. Die Aktivierung von CSF1R inhibierte miR-34a über STAT3. Die 
CSF1R-Aktivierung war ausreichend und notwendig für EMT, Migration, Invasion und 
Metastasenbildung von KRK-Zellen. Die erworbene 5-FU-Resistenz von KRK-Zellen 
wurde durch CpG-Methylierung von miR-34a und die daraus resultierende Induktion 
von CSF1R vermittelt. Beide Veränderungen waren für EMT, Invasion und 
Metastasierung von 5-FU-resistenten KRK-Zellen erforderlich. In primären KRKs 
wurde eine erhöhte Expression von CSF1R an der Invasionsfront nachgewiesen und 
war mit der CpG-Methylierung des miR-34a-Promotors sowie der Bildung von 
Fernmetastasen verbunden. Zusammenfassend lässt sich sagen, dass die hier 
identifizierte wechselseitige Regulation von miR-34a und CSF1R die EMT, 
Metastasierung und Chemosensitivität von KRK-Zellen steuert. 
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